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ABSTRACT 
Fetal origins of adult disease hypothesis states that adverse influences early in 
developmental period and particularly during intrauterine life can result in permanent 
changes in physiology which may lead to increased disease risk of chronic diseases in 
adulthood. Both fetal and adolescent period are critical time periods for development of 
lungs. Any adverse environmental exposures during these critical periods of lung growth 
is a form of programming which can have long term effects on pulmonary function. The 
purpose of this dissertation was to examine the association between different 
environmental exposures and pulmonary function in children and late adolescents. The 
first objective was to investigate the association between sensitization to house dust mites 
(HDM) allergen on skin prick test (SPT) and pulmonary function during late adolescence 
(18 years of age) within the birth cohort of Isle of Wight (IOW). The second objective 
was to assess the combined effects of maternal smoking during pregnancy and adolescent 
smoking on pulmonary function in late adolescence. This association was also tested in 
the birth cohort of IOW at 18 years of age. The third objective was to examine 
relationship between body burden of dichlorodiphenyl dichloroethene (DDE) and 
pulmonary function in pre-adolescent children (8-10 years of age) from federal state of 
Hesse, Germany.  
The results from the first objective suggested that there exists an inverse dose 
response relationship between wheal diameter (immunological response obtained on SPT
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 to HDM allergen) and pulmonary function parameters- forced expiratory volume in one 
second (FEV1), ratio of forced expiratory volume in one second over forced vital capacity 
(FEV1/FVC) and forced expiratory flow at 25-75% (FEF25-75%). Stratified analysis by 
history of asthmatic wheezing episodes showed reduced FEV1 and FVC in individuals 
with no history of asthmatic wheezing attacks.  
For the second objective we found that the offspring of mothers who smoked 
during pregnancy are more likely to smoke during adolescence. Results showed that in 
girls maternal smoking during pregnancy and adolescent smoking had both independent 
and joint inverse effects on FEV1, FEV1/FVC ratio and FEF25-75% when compared with no 
exposure. Path analysis demonstrated that the effects of maternal smoking during 
pregnancy in girls were mediated through height, weight and adolescent smoking. In 
boys, adolescent smoking had direct inverse effect on FEV1/FVC ratio and effects of 
maternal smoking were mediated through its effects on adolescent smoking. 
Results from the third objective demonstrated that DDE had crude inverse 
associations with height, weight, FEV1 and FVC in children of age 8-10 years. Further 
analysis showed that although DDE exposure did not affect pulmonary function directly 
in children, it had indirect effect on pulmonary function mediated through height and 
weight at age 8-10 years.  
Children are particularly susceptible to environmentally induced lung diseases. 
All three environmental exposures studied in this dissertation showed adverse effects on 
pulmonary function during childhood and late adolescence. These findings indicated that 
the wheal diameter on SPT which is mostly used to determine sensitivity to HDM 
allergen could also serve has an indicator of underlying abnormal pulmonary function 
viii 
even in individuals without asthma symptoms. Second objective showed that exposure to 
gestational and adolescent smoking lead to reduced flow in mid as well as large airways. 
Adolescent girls were more vulnerable to smoking effects than boys. Finally, the use of 
path analysis improved the understanding of underlying directional or non-directional 
relationships between height, weight and DDE exposure on pulmonary function. These 
findings have implications in the areas of environmental epidemiology, respiratory 
epidemiology and child health epidemiology.
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CHAPTER 1 
INTRODUCTION 
It is a well-known fact that the environment we live in plays an important role in 
determining our health. Children in particular are more vulnerable to environmental 
effects because most of the time they have no control over their prenatal or postnatal 
environment including the quality of the air they breathe, the water they drink, the food 
they eat, and their place of residence. The lungs are a common site of environmentally 
induced diseases. Epidemiological studies in last 40-50 years have shown a worrying 
increase of respiratory disorders in children. According to European Respiratory 
Society’s report, about one-quarter of primary care consultations among children relate to 
respiratory complaints and asthma and allergic disorders are the most common form of 
respiratory disorders in children.1 
Epidemiological studies have provided evidence that a number of environmental 
factors contribute in the development of asthma.2-4 These include family history of 
asthma,5,6 indoor allergens,7-9 air pollutants,10-12 tobacco smoke,13-17 prenatal factors18-20 
and exposure to chemical irritants.21 These environmental factors are considered not only 
to result in a higher prevalence of asthma in children but are also associated with 
reduction in pulmonary function in children. Studies have shown that infants who had 
family history of asthma had lower pulmonary function and increased airway 
hyperreactivity.6,22 Evidence from other epidemiological studies also suggest that risk
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 factors such as a positive reaction to allergy skin test,23,24 air pollution,25,26 maternal 
smoking during pregnancy and personal smoking by adolescents may lead to reduction in 
pulmonary function in adolescents and adults.13-17 
The respiratory tract has a resilient immune system which can reduce the effect of 
potentially harmful inhaled environmental pollutants mentioned above. However, the 
protective mechanism can overcome depending on type, duration and concentration of 
pollutant, genetic predisposition, other co-existing conditions, demographic factors such 
as age, sex, race, socio-economic status, etc. The breakdown of the immune system may 
set a chain of acute reactions such as inflammation, swelling and acute cellular response 
characterized by infiltration of neutrophils. If the acute phase remains unresolved this 
leads to proliferation of immune cells and connective tissue resulting in granulomas and 
fibrosis and ultimately remodeling of the airways. Chronic cytokine mediated 
inflammation is also known to alter the physiology of smooth muscles of airways causing 
smooth muscle cells proliferation along with increased contractility and reduced 
relaxation.27 These inflammatory and structural changes may cause remodeling of 
airways and impairment in lung volumes and airflow which are detected through 
pulmonary function tests (PFTs) or spirometry. PFTs are a valuable tool for evaluating 
the respiratory system and play a vital role in screening and assessing the severity of 
asthma by providing accurate measurements of air volume and airflow. PFTs are widely 
used in population based studies investigating environmental exposures and pulmonary 
function in children and adults.25,26,28-30  
In this dissertation, my aim was to study the associations between three such 
environmental exposures or reaction to allergen and pulmonary function in children, 
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namely reactivity on skin prick test (SPT) to house dust mites (HDM) allergen, the 
combined effect of maternal smoking during pregnancy and current smoking by 
offspring, and dichlorodiphenyl dichloroethene (DDE).  
Literature Review 
House Dust Mite 
House dust mites (HDM), Dermatophagoides pteronyssinus (Der p), is one of the 
most common indoor allergen.31 HDM allergy is a significant public health problem 
affecting 60-130 million of the world’s population and HDM are predominantly found in 
warm and humid climate.32 A study conducted in New South Wales province of Australia 
demonstrated that children of age 8-11 years living in coastal region where climate was 
more hot and humid had higher prevalence of sensitivity to HDM than children living in 
inland areas.33 The European Community Respiratory Health Survey- I reported that the 
mean prevalence of sensitization to HDM was 21.7 % in 15 European countries.34  
There is strong evidence of a link between HDM sensitization and asthma.9,33,35-40 
A meta-analysis study reported a high overall prevalence of asthma (21 %) with HDM 
sensitization.41 Sporik et al. have suggested a causal association between HDM exposure 
during infancy and development of asthma in early childhood.42 In addition, a 
randomized controlled trial showed that children who were provided with zippered vinyl 
cover for pillows, mattresses and box springs and instructions to make bedrooms house 
dust free showed fewer wheezing episodes and lower peak expiratory flow rate than 
children who were not provided with intervention.43  
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Custovic et al. reported that levels of HDM found in beddings and mattresses 
were negatively correlated with the achieved percent of the predicted values of forced 
expiratory volume in one sec (FEV1) and bronchial hyperreactivity.
44 However, the 
evidence from large birth cohort studies suggests that mere exposure to HDM is not 
sufficient to ‘cause’ asthma but it is the ability to mount immunological response to 
HDM allergen and genetic predisposition of individual that determines the risk of 
asthma.45-47 Langley et al. reported that asthmatics who were exposed and sensitized to 
HDM had a more severe form of asthma in terms of lower percent predicted FEV1 and 
higher BHR than those who were exposed but not sensitized.24 The American Thoracic 
Society (ATS) recommends use of fractional exhaled nitric oxide (FeNO) which is 
considered as an indirect marker of airway inflammation in the diagnosis of eosinophilic 
airway inflammation as well as monitoring of airway inflammation in asthmatics.48 
Studies have shown that there is a strong positive association between HDM sensitization 
and fractional exhaled nitric oxide (FeNO) levels.35-37,39 
The immunological responses to HDM are mediated through both innate and 
adaptive immune system.49-51 The mechanism of how HDM exposure induces innate 
response is still unclear. Mechanisms like activation of dendritic cells (DC), C-type lectin 
pathway and protease signaling along with Toll-like receptors (TLRs) and NOD-like 
receptors (NLRs) are suggested to induce innate immunity.49-51 The adaptive immune 
response is characterized by immunoglobin E (IgE) production along with recruitment of 
IL-4, IL-5, and IL-13.49 SPT measures response of HDM specific IgE if an individual is 
sensitized to HDM. Not only there is a dose-response relationship between increasing 
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exposure to house dust mites and having a positive SPT to HDM but individuals with 
positive SPT have higher risk for developing asthma.9,42,52  
Evidence from animal and human studies suggest that chronic exposure to indoor 
allergens may lead to mucosal inflammation of the airways which in turn could result in 
remodeling of both larger and smaller airways.53-56 HDM has been specifically implicated 
in the remodeling of airways through its role in activation of epithelial-mesenchymal 
transition (EMT) mechanism which is central to the structural changes in airways.49,57,58 
Airway remodeling characterized by epithelial changes, thickening of the basement 
membrane, hyperplasia of smooth muscle along with mucus-secreting and goblet cells, 
and increased airway vascularity may lead to irreversible loss of pulmonary function.59  
The bulk of literature on HDM has focused on prevalence of asthmatic symptoms, 
severity of asthma and bronchial hypersensitivity (BHR). Some studies have 
demonstrated that FEV1 is reduced in asthmatic patients exposed and sensitized to 
HDM.24,44,60 There is also a positive correlation between size of wheal on SPT and IgE 
and FeNO levels.36,61 Additionally, one study found that clinical severity of asthma 
increased with increased wheal size on SPT to HDM.62 Nevertheless, it is unknown 
whether degree of sensitization to HDM i.e. the wheal size on SPT has a quantitative 
association with pulmonary function. Although FEV1 is considered as important 
pulmonary function measurement related to asthma, studies have shown that forced 
expiratory flow at 25 to 75% (FEF25-75%) could detect slight airway obstruction in 
asthmatic children with normal FEV1.
63,64 Another study demonstrated a reduced FEF25-
75% in young adults diagnosed with allergies to HDM, cats and dogs but normal FEV1, 
FVC and FEV1/FVC ratio and no asthma symptoms.
65 Therefore, it is possible that 
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children sensitized to HDM may not have asthmatic symptoms and reduced FEV1; but 
have reduction in FEF25-75%.  
Additionally, studies have reported that the dose-response relationship between 
allergen exposure and sensitization is not linear.45,66,67 So it is important to assess the 
effects on pulmonary function at different levels of sensitizations for example –mild, 
moderate, and severe. To our knowledge no population-based study has explored the 
quantitative association between degree of sensitivity to HDM and pulmonary function 
parameters, namely forced vital capacity (FVC), FEV1, FEV1/FVC ratio and FEF25-75%. 
Our aim is to investigate these associations in hypothesis one of this dissertation. 
Maternal smoking during pregnancy and adolescent smoking 
The development of the lungs is long and complex process which starts during the 
4th week of gestation and continues into late adolescence/early adulthood. While growth 
of airways is mostly completed in-utero, the development of alveoli is completed by 2 
years of age and after that growth in lung volumes is mainly due to increase in size of 
alveoli and not number.68-70 During adolescence, in boys, lung and thoracic development 
occurs during and until the end of puberty while in girls, lung development is almost 
finished following menarche.71 Therefore, both fetal and adolescent period are critical 
time periods for development of lungs. Any adverse environmental exposures during 
these critical periods of lung growth is a form of programming which can have long term 
effects on pulmonary function. Maternal smoking during pregnancy and adolescent 
smoking are two such exposures which could have a repeated and/or long term damaging 
effects on the lungs. 
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Maternal smoking during pregnancy constitutes a public health problem as the 
most important in-utero harmful exposures. Smedberg et al. reported an overall smoking 
prevalence of 26 % in pregnant women in 15 European countries.72 Adverse effects of 
maternal smoking during pregnancy is not just limited to pregnancy outcomes and fetal 
growth retardation but several studies have shown that maternal smoking could also 
increase the risk of cardio-pulmonary and behavioral disorders in offspring during 
childhood.73,74 Smoking is also a growing public health problem in adolescents as more 
adolescents take up smoking every day.75,76 According to the World Health Organization 
(WHO), the prevalence of tobacco use among adolescents aged 13-15 years is 20 % in 
boys and 15 % in girls in Europe.76 Current survey data from United Kingdom indicates 
that about 207,000 children aged between 11-15 years starts smoking every year.75  
The underlying patho-physiological mechanisms of adverse effects of tobacco 
smoke are well documented. Persistent exposure to smoking causes inflammation and 
epithelial changes in bronchial tissues which leads to secretory congestion and fibrosis 
causing remodeling of airways and destruction of alveoli resulting in loss of gas 
exchange.77 Although no histological study describing the pathological effects of 
maternal smoking on the airway development during fetal period have been conducted in 
humans, one can hypothesize that smoking will adversely affect the development of lungs 
during the gestational period as a result of blood flow restriction to the placenta due to 
nicotine induced vasoconstriction, poor nutritional status of the mother associated with 
the anorexigenic effect of nicotine and carbon monoxide exposure.78 An animal model 
presented by Rehan et al. to study the effects of maternal smoking on fetal lung 
development showed that in-utero exposure to tobacco smoke alters the normal 
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homeostatic epithelial-mesenchymal interaction in the developing alveolus, resulting in 
production of myofibroblasts in larger as well as smaller airways, which is a common 
finding in asthma and chronic lung disease.79  
Evidence from several sources show that maternal smoking during pregnancy 
leads to a higher risk of recurrent lower respiratory symptoms80-83 and increases risk of 
asthma attacks during infancy and early childhood.3,18,84 Some studies have also 
demonstrated a reduced pulmonary function in adolescents exposed to maternal smoking 
during in-utero period.85-87 Additionally, Jaakkola et al. reported that maternal smoking 
during pregnancy was associated with high prevalence of childhood asthma and these 
effects were mediated through the negative effects of maternal smoking during pregnancy 
on fetal growth in seven years old Finnish children.88 Adolescent smoking on the other 
hand has been associated with dose-related decline in pulmonary function and also 
increased risk of new-onset asthma.13-16 Smoking also has differential effects in 
adolescent males and females. Even though pulmonary function decreased with increase 
in smoking in both boys and girls, girls were considered to be more vulnerable to the 
effects of smoking on pulmonary function growth than boys.14,89 A study also found that 
with increased urinary cotinine levels in boys (age 6-8 years) exposed to household 
smoking there was increased bronchial hyperresponsiveness represented by increased 
percentage ratio of the amplitude over the mean (AVAM) of the diurnal peak flow 
rates.90 However, these results were not seen in girls. 
Furthermore, it has been suggested that maternal smoking during pregnancy can 
influence smoking in offspring.91,92 Kandel et al. found that adolescent daughters of 
mothers who smoked during pregnancy were more likely to smoke in their adolescence 
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and that this association was significantly dose related.92 Additionally, they found that 
maternal smoking influence on adolescent smoking was stronger than paternal smoking 
and also stronger in female children than male children.91 
In line with this research few studies have investigated the combined effects of 
maternal smoking during pregnancy and personal smoking by adolescents on pulmonary 
function. Gilliland et al. found that children between age 8-15 years who smoked 
regularly and who were also exposed to maternal smoking during pregnancy had a more 
than eight fold increased risk of new-onset asthma than non-smokers.13 Hayatbakhsh et 
al. reported that in-utero exposure to maternal smoking was associated with a reduction 
in FEV1 and FEF25–75% in males of 21 years after accounting for maternal smoking after 
pregnancy and smoking by children at age 14 years.93 Rizzi et al. found a mild airway 
obstruction in adolescent male smokers and deficit in smaller airway function in passive 
smokers who were additionally exposed to maternal smoking during pregnancy.94  
However, another study found no effect of either current adolescent smoking or maternal 
smoking during pregnancy on pulmonary function.95 
Since maternal smoking during pregnancy and personal smoking by adolescents 
are closely associated,91,92 personal smoking by adolescents may act as a mediating 
variable in the “causal” pathway between maternal smoking during pregnancy and 
pulmonary function in adolescents (Figure 1.1). Additionally, maternal smoking during 
pregnancy has also been associated with reduced height and increased obesity in 
children96-98 which in turn is associated with pulmonary function99-102 making height and 
weight possibly intervening variables. The inconsistent results in association between 
maternal smoking during pregnancy and pulmonary function in adolescents may be 
10 
attributed to the fact that most of the traditional regression analyses methods used to 
analyze gestational and adolescent smoking are inflexible and cannot take intervening 
variables into consideration. To elucidate these complex relationships path analysis or 
structural equation models provides an approach using multiple mathematical equations. 
Path analysis is very flexible; a variable acting as an independent variable in one equation 
can act as a dependent variable in another equation, thus allowing to include intervening 
or mediating variables in the model.103 Finally, these multiple linear regression equations 
generates the direct, indirect and total effects of each variable on the outcome which can 
be used to develop causal path diagram.103,104 In our second hypothesis we aim to 
improve the assessment of gestational and adolescent smoking for lung function in 
children using path analyses. 
 
 
 
 
 
Figure 1.1: Causal pathway between maternal smoking during pregnancy, adolescent 
smoking and pulmonary function  
 
Dichlorodiphenyl Dichloroethene (DDE) 
Dichlorodiphenyl trichloroethane (DDT) is a synthetic chemical belonging to 
organochlorine chemicals family and is recognized as persistent organic pollutants. DDT 
was a widely used insecticide in the world until it was banned in most developed 
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countries by the end of 1980s. However, it is still largely used in developing countries for 
malaria control and in agriculture. DDT is toxic and a major public health concern. 
Dichlorodiphenyl dichloroethene (DDE) is principal metabolite of DDT which exists in 
environment in all forms of life, humans, plants, animals, water, air and soil.105,106 
Humans are largely exposed to DDE through food chain in food stuff such as fruits, 
vegetables, fish and meat.107 DDE is highly lipophilic and has very long half-life. It 
bioaccumulates in adipose tissue to a higher extent and bloodstream and breast milk to a 
lesser extent.  
DDE is also known to have effect on three important factors related to respiratory 
health- immune function, growth and respiratory infections/diseases. Firstly, DDE may 
alter the immune function by acting on both cellular and humoral immunity.108 There is 
evidence from both animal and human studies suggesting that DDE exposure is 
associated with increased production of cytokines and nitric oxide production in 
macrophages, leading to inflammatory reactions, cytokine imbalance and immune 
dysregulation.109-111 DDE seems also associated with changes in T-cell mediated response 
involving IL-4 which can induce epithelial cell proliferation, fibrosis, and mucus 
secretion to differing extents.109,112 These immunological changes due to persistent 
exposure to DDE may lead to remodeling of both smaller and larger airways. Secondly, 
studies have shown that DDE adversely affects height and pubertal growth in children. 
Studies evaluating association between prenatal DDE exposure and postnatal growth 
have shown decreased height at ages 1, 4 and 7 years.113 Postnatal exposure to DDE has 
also been associated with decreased height in girls of age 8 years.114 Some other studies 
however, have found no such association between DDE exposure and postnatal 
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growth.115-117 DDE’s anti-androgenic properties have been known to interfere with 
puberty in both human and animal studies.116,118-120 One study has reported that in-utero 
exposure to DDE is associated with reduced age at menarche by one year.121 High levels 
of DDE have also been found in girls with precocious puberty.122 Finally, pre-natal 
exposure to DDE has been linked with respiratory disorders like lower respiratory tract 
infections, episodes of wheezing, otitis media and increased risk of asthma in early 
childhood.20,123-126  
Nevertheless, there is lack of investigations on the association between DDE 
exposure and pulmonary function. As height, which is one of the important factors 
related to pulmonary function,127 is associated with DDE exposure we can hypothesize 
that DDE exposure may have an effect on pulmonary function, either direct or via the 
influence of growth (height). Hence, in the pathway between DDE exposure and 
pulmonary function height may act as an intervening variable (Figure 1.2). 
 
 
 
 
 
 
Figure 1.2: Causal pathway between body burden of DDE, growth and pulmonary 
function 
 
Additionally, average pulmonary function growth varies greatly with height, sex 
and age in children and adolescents.128-130 Thus, it is important to take into consideration 
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relationships between various factors which may be affected by DDE exposure when 
assessing association between DDE exposure and pulmonary function. As explained 
earlier, path analyses (structural equation models) are one of the appropriate approaches 
to accommodate intervening or mediating variables in the analysis. Path analysis takes 
into account various directional and non-directional associations between a set of 
variables on outcome while estimating direct, indirect and total effects of each variable 
on the outcome. Hence, in hypothesis three, we will assess the direct and indirect of DDE 
on pulmonary function markers. 
Scope of Study 
The overall objectives of this research are to examine the association between 
three different environmental exposures, namely (1) allergic sensitization to house dust 
mite allergens (SPT to HDM), (2) maternal smoking during pregnancy (gestational 
smoking) and adolescent smoking, and (3) dichlorodiphenyl dichloroethene (DDE) and 
pulmonary function in children and adolescents. The first step was to investigate the 
association between immunological response to HDM allergen on SPT and pulmonary 
function during late adolescence within the birth cohort of Isle of Wight (IOW). The next 
step was to assess the combined effects of gestational smoking and adolescent smoking 
on pulmonary function in late adolescence. This association was also tested in the birth 
cohort of IOW. The third step was to examine relationship between body burden of DDE 
and pulmonary function in pre-adolescent children in a study conducted in the federal 
state of Hesse, Germany. In both step two and step three, we used path analysis methods 
to address the possibility of intervening or mediating variables. 
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Hypotheses and Specific Aims  
Hypothesis 1 (H-1): With an increase in wheal size (severity of sensitization) to HDM 
allergen on SPT pulmonary function decrease in adolescents of age 18 years 
 Specific Aims (SA) 1.1: To compare FEV1, FVC, FEV1/FVC, FEF25-75% and 
FeNO between those children who tested positive on HDM SPT and those who 
tested negative.  
 SA 1.2: To determine the association between increase in wheal size on HDM 
SPT and above mentioned pulmonary function parameters 
 SA 1.3: To categorize the degree of sensitization based on the wheal size and 
compare pulmonary function in these categories 
 SA 1.4: To compare pulmonary function among various groups depending on the 
duration of positive SPT  
Hypothesis 2 (H-2): Maternal smoking during pregnancy and current smoking by the 
offspring have negative effect on pulmonary function in adolescents after accounting for 
the intervening effect of current smoking by offspring  
 SA 2.1: To determine the joint and independent effects of maternal smoking 
during pregnancy and adolescent smoking on pulmonary function parameters in 
adolescents of age 18 years separately in boys and girls using linear regression 
 SA 2.2: To investigate if current smoking by adolescents act as a mediating 
variable in the “causal” pathway between maternal smoking during pregnancy and 
pulmonary function in adolescents using path-analytical models. 
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Hypothesis 3 (H-3): Persistent body burden of DDE in children affect pulmonary 
function in childhood, directly or indirectly via its effect on height and weight in children  
 SA 3.1: To determine the association between blood levels of DDE with 
pulmonary function parameters namely FEV1, FVC and FEV1/FVC 
 SA 3.2: To explore the relationship between blood levels of DDE, height, weight 
and pulmonary function using path analyses  
Significance of the study 
Hypothesis 1:  
As mentioned earlier HDM allergy is a significant public health problem in 
Western countries. Although many previous studies have shown an association between 
HDM exposure and asthma, to our knowledge, this study is one of the first to explore the 
quantitative association between wheal diameter on SPT and pulmonary function. It is 
important to extend the research on HDM beyond its association with asthma because 
any negative effects that HDM sensitization may have on pulmonary function especially 
during the growth phase of the lungs may have long term respiratory health 
consequences.  
Hypothesis 2: 
While maternal smoking during pregnancy and adolescent have been individually 
linked with lower pulmonary function during adolescence, little is known about the 
combined effects of both these factors on pulmonary function. After birth pulmonary 
function undergoes a phase of growth, reaching its peak in early adulthood. Therefore, 
both the in- utero and adolescent periods are important for the growth of the respiratory 
system. Additionally, behavioral studies have also shown an association between 
16 
maternal smoking during pregnancy and smoking by offspring. Path analysis would be 
appropriate to disentangle these complex relationships between maternal smoking during 
pregnancy, adolescent smoking and pulmonary function in adolescents. Our study is the 
first to examine these relationships using path analysis.  
Hypothesis 3: 
Given that both prenatal and postnatal DDE exposure is associated with asthma, 
an additional investigation of the association between DDE and pulmonary function will 
show whether the above association is due to immune response or can also be explained 
by pulmonary effects. DDE is known to have negative effect on height during childhood 
which may act as an intervening variable on the ‘causal’ pathway between DDE and 
pulmonary function. This association was investigated using path analysis. This study is 
the first to use robust analytical methods like repeated measures analysis and path 
analysis to assess the association between DDE and pulmonary function.  
 Study Outline 
The dissertation is divided into six chapters. The first chapter provides the 
hypotheses of the research, including specific aims, as well as the scope and significance 
of the research. The second chapter provides the methodology for each specific aim. The 
third, fourth, and fifth chapters contain hypotheses 1, 2 and 3, respectively. The final 
chapter contains a discussion of the findings, public health implications, limitations, and 
summary of the entire dissertation. 
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CHAPTER 2 
METHODS 
Addressing three different exposures of interest, we used data sets from two 
different population. Since the first two hypotheses were tested using the Isle of Wight 
(IOW) birth cohort the methods related to these two hypotheses are described together 
with the exception of the exposures and statistical analyses methods which are provided 
separately for H-1 and H-2. The third hypothesis was tested using a longitudinal study 
conducted in Germany; its methods are presented separately.  
SAS Version 9.3 (SAS Institute, Cary, NC, USA) was used for all statistical 
analysis. 
Hypotheses 1 and 2: 
Study Population 
The IOW birth cohort was established with the aim to study the natural history of 
asthma and allergic conditions. The island is close to the British mainland, semi-rural, 
without heavy industry and largely composed of Caucasians (99 %). Children born 
between January 1989 and February 1990 on the IOW were recruited to participate in this 
study. In total, 1,536 mothers/child pairs born in the study period were contacted. After 
exclusion of perinatal deaths, adoptions, and refusals of informed consent was obtained
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 from 1,456 participants. Children were followed at the ages of 1 (n=1,167), 2 (n=1,174), 
4 (n=1,218), 10 (n=1,373) and 18 years (n=1,313). Detailed questionnaires were 
completed for each child at each follow-up regarding asthma and allergic conditions. 
When a visit was not possible, a telephone questionnaire was completed or a postal 
questionnaire sent for completion and return. Ethics approval was obtained from the Isle 
of Wight Local Research Ethics Committee at recruitment of this birth cohort born on the 
Isle of Wight, United Kingdom, between January 1989 and February 1990. Additional 
approval was acquired for year 1 and 2 follow-ups (No 05/89; dated 08/22/1988) and the 
Ethics Committee approved an extension for this study to allow follow-up at 4 years 
(dated 01/17/93). Subsequently, at 10 years follow-up, we obtained permission from the 
Isle of Wight Local Research Ethics Committee for the follow-up as well as collection of 
blood for genetic studies into asthma and allergy (No. 18/98, dated 07/20/1998). For the 
18-year follow-up, ethics approval was given by the Isle of Wight, Portsmouth and SE 
Hampshire Local Research Ethics Committee (No. 06/Q1701/34, dated 06/16/2006).130-
132 
Exposures 
Hypothesis 1: Skin Prick Test (SPT) for HDM 
To determine allergic sensitization status, SPT at ages 1 and 2 years were 
performed on children with any symptoms of eczema, asthma or rhinitis. SPT were also 
performed at ages 4, 10 and 18, regardless of symptoms on most children enrolled in the 
study by a standardized method to a panel of common indoor and outdoor allergens: 
house dust mite (Dermatophagoides pteronyssinus), grass pollen mix, tree pollen mix, cat 
and dog epithelia, Alternaria alternata, Cladosporium herbarum, milk, hens’ egg, wheat, 
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soya, cod and peanut and, in addition, histamine and physiological saline acted as the 
positive and negative controls respectively (Alk-Abello, Horsholm, Denmark). Single-
headed lancets were used and the skin pricked at an angle of 90°. The wheal diameter 
was recorded at 15 minutes.133 Primarily, we used results from HDM SPT performed at 
18 years of age. We used sensitization to HDM as both continuous and categorical 
variable of exposure. For SA 1.1, we categorized individuals into two groups based on 
their wheal size on SPT- positive (≥ 3 mm) and negative (< 3 mm). For SA 1.2, the actual 
size of wheal diameter (mm) on SPT was used as exposure. For SA 1.3, in order to 
determine degree of sensitization we categorized wheal size into 3 categories: >5 mm 
diameter (moderate/severe), 3-5 mm diameter (mild) and < 3 mm diameter (no 
sensitization). For SA 1.4, to test whether longer duration of having a positive SPT 
affects pulmonary function we divided individuals into 3 groups- SPT positive at age 18 
years only, SPT positive since age of 10 years, and SPT positive since age of either 4 or 2 
or 1 years. For the simplicity, we labeled these groups as diagnosed with positive SPT 
during late-adolescence, pre-adolescence and early childhood, respectively. 
Hypothesis 2: Maternal smoking during pregnancy and current smoking by adolescents 
of age 18 years 
The main exposures of interests were maternal smoking during pregnancy and 
current personal smoking by adolescents of age 18 years. Birth and obstetric records were 
used to obtain information on maternal smoking during pregnancy. To determine the 
current smoking status children were asked “Do you currently smoke?” at age 18 years. 
Information was also collected on number of cigarettes smoked per day, past smoking 
and duration of smoking. Pack years were calculated from cigarettes smoked per day and 
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duration of smoking and used as main indicator of current smoking at 18 years of age. 
Adolescent smoking was defined as a history of ever smoking more than 100 cigarettes. 
To investigate the independent and joint effects of maternal smoking during pregnancy 
and adolescent smoking we categorized exposure into the following mutually exclusive 
categories: none, exposure to maternal smoking only, adolescent smoking only and 
exposure to both maternal smoking and adolescent smoking. This is comparable to a prior 
categorization used by Sadegnejad et al. to combine exposure to maternal smoking 
during pregnancy and environmental tobacco smoke in the cohort of IOW at age 10 
years.134 
Outcomes 
Pulmonary function parameters 
Pulmonary function tests were performed at 10 and 18 years of age. FVC, FEV1, 
FEF25-75% and PEFR were measured using a Koko Spirometer and software with a 
portable desktop device (both PDS Instrumentation, Louisville, KY, USA). Spirometry 
was performed and evaluated according to the American Thoracic Society (ATS) criteria. 
Children were required to be free of respiratory infection for 2 weeks and not to be taking 
any oral steroids and were advised to abstain from any β-agonist medication for 6 hours 
and from caffeine intake for at least 4 hours.130-132 
Fractional exhaled nitric oxide (FeNO) measurements 
FeNO was measured (Niox mino, Aerocrine AB, Solna, Sweden) according to 
ATS guidelines.48 A biofeedback mechanism was used to maintain the expiratory flow 
rate at 50 ml/s and subjects exhaled against resistance to prevent upper airway 
contamination. Measurements were made in a standardized manner with the subject 
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standing without a nose clip; FeNO was measured before spirometric testing. Participants 
were rescheduled if they had clinical symptoms consistent with either current infection or 
a recent (within 2 weeks) asthma exacerbation, or had required antibiotics or oral steroids 
in the preceding 2 weeks.133 
Covariates 
Birth weight, sex, height, weight, body mass index (BMI), use of oral or inhaled 
steroids, parental history of asthma and allergic conditions, active smoking at 18 years, 
exposure to environmental tobacco smoke (ETS) at 18 years, and socio-economic status 
(SES) were considered as potential confounders and were adjusted in explanatory 
models. Information on birth weight was obtained from the hospital records. Height and 
weight were measured before the spirometric tests at age 18; BMI was calculated. 
Information on use of oral or inhaled steroids, parental history of asthma and allergic 
conditions were inquired from the study participants at age 18 Exposure to ETS at age 18 
was inquired from questions of “any smoking in the household”. Information on the SES 
was based on the following three variables: (a) the British socioeconomic classes (1–6) 
derived from parental occupation reported at birth; (b) the number of children in the 
index child’s bedroom (collected at age 4 years); and (c) family income at age 10 
years.131 Additionally, adjustment for sensitization to other indoor and outdoor allergens, 
namely cats, dogs, grass pollen, tree pollen, Alternaria alternata, Cladosporium 
herbarum, milk, hens’ egg, wheat, soya, cod and peanut was also done. A participant was 
considered atopic if he/she had a positive SPT to any of these allergens.  
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Statistical Analysis 
Of total 1,456 participants 838 went through spirometry tests at 18 years of age. 
To address the issue of missing data on one or more confounders we used multiple 
imputations procedure PROC MI with multivariate normal distribution to generate ten 
new data sets. SAS uses Markov Chain Monte Carlo (MCMC) which assumes that all the 
variables in the imputation model have a joint multivariate normal distribution. For the 
continuous variables we generated the missing values which ranged between the 
minimum and maximum observed values.  
Hypothesis 1: 
For specific aims related to H-1linear regression techniques were used to 
determine association between exposure to HDM and pulmonary function parameters- 
FEV1, FVC, FEV1/FVC ratio, FEF25-75% and FeNO at 18 years of age. The analysis for 
imputed data sets were performed in two steps when the exposure was continuous (SA 
1.1) and in three steps when exposure was categorical (SA 1.2, 1.3 and 1.4). The first step 
was to obtain data sets containing parameter estimates by PROC MIXED on each 
imputed data set. We did not use general linear model analysis (PROC GLM) because 
PROC GLM does not support imputation of categorical variables without monotone 
missing pattern. Using PROC MIXED did not add any additional concerns and was more 
flexible. Additionally, when the exposure variable was categorical (SA 1.2, 1.3 and 1.4) 
we also obtained estimates for least square means and standard errors in step one. Next 
we used PROC MIANALYZE to combine the parameter estimates from each imputed 
data set and generate valid statistical inferences about the parameters. In the third step 
(only for categorical exposure) we again used PROC MIANALYZE to compare least 
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square means for categorical exposure variable based on least square means estimates and 
standard errors obtained from each imputed data set in step one.  
We adjusted for the effects of sex, height, weight, BMI, sensitization to other 
indoor or outdoor allergens, use of oral or inhaled steroids, parental history of asthma and 
other allergic conditions, active smoking, exposure to ETS and SES. We also stratified 
analysis according to history of asthma wheezing attacks. We selected those 
confounders/effect modifiers which changed the estimates by 10 %.  
Hypothesis 2: 
To test H-2 we again used imputed data sets and followed the 3 step analysis plan 
as in H-1. For SA 2.1, in the first step we used PROC MIXED model to obtain the 
parameter estimates for each imputed data set separately in boys and girls. To investigate 
the independent and joint effects of both maternal smoking during pregnancy and 
adolescent smoking, we used exposure with mutually exclusive categories: none, 
exposure to maternal smoking only, adolescent smoking only and exposure to both 
maternal smoking and adolescent.  
In the next two steps we used PROC MIANALYZE to generate valid parameter 
and least square means estimates. The models were adjusted for birth weight, current 
weight, atopy, parental history of asthma, exposure to ETS and SES. We used backward 
elimination method and selected the confounders/effect modifiers that changed the 
estimates by 10 %. To account for the differential effects of lung growth with respect to 
sex and height we used interaction term between sex and height. As explained earlier 
current smoking by adolescents, height and weight may act as mediating variables in the 
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“causal” pathway between maternal smoking during pregnancy and pulmonary function 
in adolescents. To explore this further in SA 2.2 we used path analysis and specifically 
the Covariance Analysis of Linear Structural Equations (PROC CALIS). Path analysis 
provides an approach based on conceptual model and multiple mathematical equations. 
Path analysis is very flexible; a variable acting as a cause in one equation can act as an 
effect in another equation, thus allowing to include intervening or mediating variables in 
the model. These multiple linear regression equations generates the direct, indirect and 
total effects of each variable on the outcome which can be used to develop causal path 
diagram. While direct effects represent the association between exposure and outcome 
without any intervening/mediating variables, indirect effects represent the association 
between exposure and outcome via intervening/mediating variables. The total effects of 
exposure on outcome is obtained by adding direct and indirect effects. We used Full 
Information Maximum Likelihood (FIML) method to determine parameter estimates 
which addresses the issue of missing values for covariates. Pack years was used as an 
indicator of adolescent smoking in all path analysis models. The adequacy of model fit 
was determined by several statistics: a chi-square p-value > 0.05 if chi-square test statistic 
is close to 0, comparative fit index (CFI) > 0.9, adjusted goodness of fit index (AGFI) > 
0.9 and root mean square error of approximation (RMSEA) < 0.06.. 
Hypothesis 3: 
Study Population 
We used data from a longitudinal study conducted in the south of the federal state 
of Hesse, in central Germany, between 1994 and1997. Children were recruited from 3 
different regions. One is in the Rhine Valley, with low mountains on both sides, within a 
 25 
15-km radius around an industrial waste incinerator and is also used intensively for 
vegetable production. A second region, also industrial and agricultural, is 20 km north of 
the incinerator area. The third region is located in low mountains (about 400 m above sea 
level).114 After obtaining permits from the Data Protection Agency of the State of 
Hamburg, Germany, from the Ministry of Cultural Affairs of Hesse, Germany, and from 
the local school committees, parents of 1091 second grade school children in 18 townships 
were asked to participate in this study. Informed consent, according to the requirements of 
the Ethical Committee of the Board of Physicians and the Data Protection Agency of the 
State of Hamburg, was obtained from all participating parents. Parents were asked to let 
their children participate in phlebotomy only when passive smoking in the private 
household had not exceeded 10 cigarettes per day in the previous 12 months. Children and 
their parents participated in the 3 repeated surveys (December 1994–April 1995, January 
to May1996, January to June 1997).114  
Exposure 
Organochlorines in Blood  
A blood sample was taken as part of the first visit. DDE and 7 PCB congeners 
(101, 118, 138, 153, 170, 180, 183, and 187) were analyzed at the Institute of 
Toxicology, University of Kiel, Germany. DDE and PCB concentrations were 
determined from 5-mL samples of whole blood by performing high-resolution gas 
chromatography (HRGC, Model 3400, Varian, Gloucester, Mass) with a 63Ni electron 
capture detector. The detection limit (the signal/low-noise ratio) was 0.02 g/L for DDE 
and each PCB congener. For extraction and clean-up procedures, magnesium-silica gel 
and n-hexane were used (9 g of silica gel was deactivated with 3 % water and given in a 
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chromatography column 22 mm in diameter and 48 mm in length for elution). The 
capillary column amounted to 30 m in length and 0.25 mm in diameter, containing 
nitrogen as a carrier gas. The congeners were determined by retention times on the 
chromatograms and were identified by comparison with known standards. In addition, 
reliability was tested with gas chromatography– mass spectometry. The laboratory 
successfully participated in nationwide interlaboratory quality assessments in Germany 
for DDE and PCB determinations.114  
Outcomes 
Pulmonary function parameters 
Pulmonary function tests were conducted at 8, 9 and 10 years of age using a 
Masterscope (Software Release 4.0; Erich Jaeger, Würzburg, Germany). The instrument 
was calibrated daily and each child performed two forced expiratory maneuvers 
according to the ATS guidelines in standing position wearing a nose clip. Two 
flow/volume curves were accepted as reproducible if the difference between FVC 
measurements was ≤ 5 %. The highest FVC and FEV1 values were then selected for 
statistical analysis.  
Covariates 
Self-administered questionnaires were used in the survey. Information was 
collected on child’s age, birth weight, birth order, maternal and paternal education, 
maternal and paternal height and smoking during pregnancy, and breast-feeding duration. 
Height and weight were measured for each child in 3 consecutive examinations 1 year 
apart (ages of 8, 9, and 10 years). Environmental tobacco smoke (ETS) was assessed as 
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smoking in the child’s home in the previous 12 months (per day: no cigarettes, 1-10 
cigarettes, 11-20 cigarettes, 20-30 cigarettes, >30 cigarettes).114 
Statistical Analysis 
Out of 691 enrolled children, 632 performed PFTs in year 1995, 598 in year 1996 
and 558 in year 1997. However, DDE was measured only in years 1995 and 1997. About 
328 (52 %) children in 1995 and 214 (61.7 %) children in 1997 who had PFT also had 
information on DDE. From year 1996, we selected children who also participated in PFT 
(n=328) either in 1995 or 1997. Since, DDE exposure was not measured in 1996 we 
imputed values for those children based on their respective values in years 1995 and 1997 
using multiple imputation methods. Multiple imputations were also used for missing data 
on one or more confounders. As a first step, correlations between DDE exposure and 
height, weight, FEV1, FVC and FEV1/FVC were determined using PROC CORR method. 
For SA 3.1, we used linear mixed models (PROC MIXED) to assess the 
association between blood levels of DDE and repeated pulmonary function 
measurements. Compound symmetry covariance structure matrix was selected based on 
lowest Akaike information criteria and the Bayesian Schwarz information criterion after 
considering unstructured, compound symmetry and autoregressive covariance structure 
matrices. All models were adjusted for sex, birth weight, breast feeding duration, height, 
weight, smoking during pregnancy, parental history of asthma and ETS. We used 
backward elimination method to select and keep the confounders in the model that 
changed the estimates by 10 %. Since relationship between pulmonary function and 
height varies by sex we included interaction between height and sex in explanatory 
models.  
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The possibility that effect of DDE exposure on pulmonary function in childhood 
is mediated through its effect on height cannot be tested using repeated measurement 
analysis since these models do not take into consideration intervening variables. 
Therefore, we explored the relationship between DDE exposure, height, weight and 
pulmonary function in childhood by path analysis using the Covariance Analysis of 
Linear Structural Equations procedure (SA 3.2). However, since body burden of DDE, 
height and weight are correlated we were not able to generate positive convergence 
estimates for maximum likelihood optimization method. Therefore, we performed two 
separate path analysis model on cross-sectional data for years 1995 and 1997 using Full 
Information Maximum Likelihood (FIML) method which takes into consideration the 
missingness. The adequacy of model fit was determined by the following statistics: a chi-
square p-value > 0.05 if the chi-square value is close to zero which indicates little 
difference between the expected and observed covariance matrices comparative fit index 
(CFI) > 90, adjusted goodness of fit index (GFI) > 90 and root mean square error of 
approximation (RMSEA) < 0.06 (SUGI).
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CHAPTER 3 
RELATIONSHIP BETWEEN IMMUNOLOGICAL RESPONSE TO HOUSE DUST 
MITE SENSITIZATION AND PULMONARY FUNCTION IN LATE 
ADOLESCENCE 
Introduction 
House dust mites (HDM) allergy is a significant public health problem in the 
Western countries.32,34 A survey conducted in four European countries showed that 15 % 
of the survey population presenting with allergy symptoms like repetitive sneezing, nasal 
discharge, stuffy nose, etc. had physician diagnosed allergy to HDM.135 The role of HDM 
in the pathogenesis of asthma has been extensively studied and results have shown a 
positive association between exposure and sensitization to HDM and prevalence of 
asthma symptoms, severity of asthma and bronchial hyperreactivity (BHR).9,35-40,60 Some 
studies have even suggested a causal association between HDM exposure and 
development of asthma in early childhood.42,43 Additionally, There is also a strong 
positive relationship between HDM exposure and fractional exhaled nitric oxide (FeNO) 
levels which is an indirect marker of airway inflammation and used for monitoring 
treatment in asthma.35,36 
Custovic et al. reported that levels of HDM found in beddings and mattresses 
were negatively correlated with percent predicted values of forced expiratory volume in 
one
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 sec (FEV1) and bronchial hyperreactivity.
44 However, the evidence from large birth 
cohort studies suggests that mere exposure to HDM is not sufficient to ‘cause’ asthma but 
it is the ability to mount immunological response to HDM allergen and/or the genetic 
predisposition that determines the risk of asthma.24,45-47 This ability to mount 
immunological response to HDM allergen can be measured in terms of wheal size on skin 
prick test (SPT) and is mediated through immunoglobulin E (IgE). There seems to be a 
dose-response relationship between increasing exposure to house dust mites and having a 
positive SPT to HDM.9,42,52 It has also been reported that total serum IgE and allergen 
specific IgE are inversely associated with pulmonary function in both children and 
adults.136-138 Additionally, a study also observed an increased severity of asthma with 
increased wheal size on SPT for HDM.62  
Evidence from animal and human studies suggest that chronic exposure to indoor 
allergens leads to mucosal inflammation and remodeling of both larger and smaller 
airways and ultimately may alter pulmonary function.53-56 Although FEV1 is the most 
important parameter considered when diagnosing asthma there is growing body of 
evidence suggesting role of smaller airways in pathology of asthma.139-142 FEF25-75% is a 
spirometric variable used to detect small airway obstruction. FEF25-75% has a marked 
physiological variability, but epidemiological studies suggest that FEF25-75% is an 
important pulmonary function parameter which could detect slight airway obstruction in 
non-asthmatic children with normal FEV1.
63,64 Another study demonstrated a reduced 
FEF25-75% in young adults diagnosed with allergies to HDM, cats and dogs but with 
normal FEV1 and no asthmatic symptoms.
65 Thus, FEF25-75% is a significant parameter 
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and a marker for early inflammatory involvement of the small airways in individuals with 
allergic disease and no asthma. 
Any exposure leading to adverse effects on pulmonary function especially during 
phase of growth might have long term consequences. Although the role of HDM in 
asthma has been well-established, it is unknown whether wheal size on SPT has a 
quantitative association with pulmonary function.  Our main aim in this study was to 
assess the association of degree of sensitization to HDM and duration of positive SPT to 
HDM allergen with pulmonary function parameters namely- FEV1, FVC, FEV1/FVC 
ratio FEF25-75% including average FeNO levels in the birth cohort of Isle of Wight (IOW) 
during late adolescence. 
Methods 
Study Population 
We used data from the IOW birth cohort. Between January 1989 and February 
1990, 1,536 mothers/child pairs were contacted to be enrolled in the IOW birth cohort 
after obtaining approval from the Isle of Wight Local Research Ethics Committee at 
recruitment. After exclusion of perinatal deaths, adoptions, and refusals and obtaining 
approval from the local research ethics committee 1,456 participants were available for 
follow-up at 1, 2, 4, 10 and 18 years of age.130,131  
Skin Prick Test for HDM 
To determine allergic sensitization status, SPT at ages 1 and 2 years were 
performed on children with symptoms of eczema, asthma or rhinitis. At ages 4, 10 and 18 
years SPT were performed regardless of symptoms on most children enrolled in the study 
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by a standardized method to a panel of common indoor and outdoor allergens: HDM, 
grass pollen mix, tree pollen mix, cat and dog epithelia, Alternaria alternata, 
Cladosporium herbarum, milk, hens’ egg, wheat, soya, cod and peanut. Histamine and 
physiological saline acted as the positive and negative controls respectively (Alk-Abello, 
Horsholm, Denmark). Single-headed lancets were used and the skin pricked at an angle 
of 90°. The wheal diameter was recorded at 15 minutes.133,143  
Pulmonary Function 
Pulmonary function tests were conducted at 10 and 18 years of age. FVC, FEV1, 
FEF25-75% and PEFR were measured using a Koko Spirometer and software with a 
portable desktop device (both PDS Instrumentation, Louisville, KY, USA). Spirometry 
was performed and evaluated according to the American Thoracic Society (ATS) criteria. 
Children were required to be free of respiratory infection for 2 weeks and not to be taking 
any oral steroids and were advised to abstain from any β-agonist medication for 6 hours 
and from caffeine intake for at least 4 hours.130-132 
Fractional Exhaled Nitric Oxide Measurements 
FeNO was measured (Niox mino, Aerocrine AB, Solna, Sweden) according to 
ATS guidelines.48 A biofeedback mechanism was used to maintain the expiratory flow 
rate at 50 ml/s and subjects exhaled against resistance to prevent upper airway 
contamination. Measurements were made in a standardized manner with the subject 
standing without a nose clip; FeNO was measured before spirometric testing. Participants 
were rescheduled if they had clinical symptoms consistent with either current infection or 
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a recent (within 2 weeks) asthma exacerbation, or had required antibiotics or oral steroids 
in the preceding 2 weeks.133 
Potential Confounders 
We considered sex, height, weight, body mass index (BMI), use of oral or inhaled 
steroids, history of asthmatic wheezing attacks, parental history of allergy, active 
smoking at 18 years, exposure to environmental tobacco smoke (ETS) at 18 years, and 
socio-economic status (SES) as potential confounders. We also adjusted for sensitization 
to other indoor and outdoor allergens, namely cats, dogs, grass pollen, tree pollen, 
Alternaria alternata, Cladosporium herbarum, milk, hens’ egg, wheat, soya, cod and 
peanut. A participant was considered atopic if he/she had a positive SPT to any of these 
allergens. Height and weight were measured before the spirometric tests at age 18; BMI 
was calculated using formula- (weight in kg)/ (height in meters). Information on use of 
oral or inhaled steroids, parental history of asthma and other allergic conditions and 
active smoking was inquired from the study participants at age 18. Exposure to ETS at 
age 18 was inquired from questions of “any smoking in the household”. Information on 
the SES was based on the following three variables: (a) the British socioeconomic classes 
(1–6) derived from parental occupation reported at birth; (b) the number of children in the 
index child’s bedroom (collected at age 4 years); and (c) family income at age 10 
years.131 
Statistical Analysis 
Of total 1,456 participants 838 went through spirometry tests at 18 years of age. 
As a first step we used t-test and analysis of variance (ANOVA).to compare pulmonary 
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function across sex, degree of sensitization and duration of sensitization categories. We 
used linear regression techniques to determine all the associations. Our outcomes of 
interest were pulmonary function parameters FEV1, FVC, FEV1/FVC ratio, FEF25-75% and 
FeNO at 18 years of age. The allergic sensitization to HDM on SPT was used as exposure 
in four different ways. First we used the wheal size (diameter in mm) obtained on SPT at 
18 years of age as a continuous variable. If SPT was not performed at 18 years of age 
then we used results from SPTs performed at 10 years of age. Next we classified SPT as 
positive and negative based on wheal diameter; mean diameter of 3 mm or more than the 
negative control was considered as positive SPT. For these analysis we also included 
interaction terms between wheal diameter/ positive or negative SPT and history of 
wheezing attacks. If the interaction terms were significant (p-value: < .0001) then we 
stratified the analysis by history of wheezing. We categorized wheal size into 3 categories 
in order to determine degree of sensitization: >5 mm (moderate/severe), 3-5 mm (mild) 
and < 3 mm (no sensitization). Finally, to test whether longer duration of having a 
positive SPT affects pulmonary function we divided individuals into 3 groups- SPT 
positive at age 18 years only, SPT positive since age of 10 years, and SPT positive since 
age of either 4 or 2 or 1 years. For the simplicity, we labeled these groups as diagnosed 
with positive SPT during late-adolescence, pre-adolescence and early childhood, 
respectively. All explanatory models were adjusted for potential confounders mentioned 
earlier. As relationship of pulmonary function with height varies with sex we also 
included the interaction term between height and sex in the explanatory models. We 
selected those confounders which changed the estimates by 10 %. To address the issue of 
missing data on one or more confounders we used multiple imputations to generate ten 
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new data sets. All data sets were analyzed separately for linear regressions. Finally all 
results were combined and valid statistical inferences were generated using 
MIANALYZE procedure. 
Results 
Out of 838 participants who had spirometry at 18 years of age 443 (52.9 %) were 
girls. Majority of participants belonged to middle social status (78.3 %) based on parental 
occupation, number of children in one bedroom and annual family income. About 28.5 % 
had history of asthma wheezing episodes, 31.7 % had history of other atopic conditions 
and 13.6 % had used steroids (nasal or oral) for asthma attacks prevention. The 
prevalence of smoking for this age group was 33 % and about 39.1 % were exposed to 
some form of ETS. About 29 % were tested positive for HDM allergy on SPT; 12.4 % 
had wheal diameter of > 5 mm, 16.5 % had wheal diameter of 3-5 mm and 71.1 % had 
wheal diameter of < 3 mm. Among those who tested positive 30.6 % had positive SPT 
since early childhood, 26.9 % had since pre-adolescence and 42.6 % were diagnosed 
during late adolescence. (Table 3.1). The average diameter of the wheal was 1.7 ± 2.6 
mm (Table 3.2). Boys had overall higher FEV1, FVC, FEF25-75% and FeNO measures than 
girls, except for FEV1/FVC ratio which was higher in girls (Table 3.3). The participants 
with positive SPT had higher FVC and FeNO levels while lower FEV1/FVC ratio (Table 
3.4). Among the group with wheal diameter > 5 mm and group with wheal diameter of < 
3 mm differences were observed for FVC and FEF25-75%; for FEV1/FVC ratio and FeNO 
levels differences were seen within all groups (Table 3.5). FEV1/FVC ratio and FEF25-75% 
were lower in the group with positive SPT since early childhood when compared to the 
groups who had positive SPT since either pre-adolescence or late adolescence. FeNO 
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levels were higher in the group with longer duration of positive SPT when compared to 
any group with lower duration (Table 3.6). 
HDM as continuous variable 
Results from the linear regression showed significant interaction between wheal 
diameter (mm) and history of wheezing for FVC, FEV1/FVC, FEF25-75% and FeNO levels 
(Table 3.7). These results were adjusted for height, weight, sex, current smoking, history 
of asthma wheezing episodes and other atopic conditions, maternal and paternal history 
of allergy, use of steroids, ETS and SES. Stratified analysis demonstrated reduction in 
FVC and FEV1 and increase in FeNO levels in participants who did not report any history 
of asthma wheezing episodes. On the other hand, in the group of participants with history 
of asthma wheezing episodes there was statistically significant reduction in FEV1/FVC 
ratio and FEF25-75% and increase in FeNO levels (Table 3.8). 
HDM as categorical variable 
The interaction between SPT (positive or negative) and history of wheezing 
episodes was also significant after adjusting for height, weight, sex, current smoking, 
history of asthma wheezing episodes and other atopic conditions, maternal and paternal 
history of allergy, use of steroids, ETS and SES (Table 3.9). The differences in least 
square means between positive and negative SPT showed significantly lower FEV1/FVC 
ratio and FEF25-75% in participants with positive SPT and history of wheezing episodes. 
No such differences were seen in other group with no history of wheezing. The average 
FeNO levels were higher in participants with positive SPT irrespective of the history of 
asthma (Table 3.10). 
 37 
Degree of sensitization 
There were significant differences in all pulmonary function parameters except 
FVC when comparing group with wheal diameter of > 5 mm to group with wheal 
diameter of < 3 mm. Additionally, FEF25-75% was also lower in group with wheal 
diameter of > 5 mm when compared to group with 3-5 mm wheal diameter. FeNO levels 
were higher in groups with higher degree of sensitization when compared to groups with 
lower degree of sensitization (Table 3.11). 
Duration of sensitization 
The group of participants who had positive SPT since early childhood had lower 
FEV1, FEV1/FVC ratio and FEF25-75% and higher FeNO when compared to group who 
tested positive in late adolescence. FEV1/FVC ratio and FEF25-75% were also lower in 
early childhood diagnosed group when compared to pre-adolescence diagnosed group. 
Lower FEV1/FVC ratio and higher FeNO were observed in pre-adolescence diagnosed 
group when compared to late-adolescence diagnosed group (Table 3.12). 
We were not able to test the differences within groups of degree of sensitization and 
duration of sensitization stratified by asthmatic wheezing status because of small size.   
Discussion 
The results of the present study show significant reductions in FEV1, FEV1/FVC 
ratio and FEF25-75% and increase in average FeNO with every 1 mm increase in wheal 
diameter on SPT at age 18 years. Stratified analysis demonstrated decline in FEV1/FVC 
ratio and FEF25-75% were limited to participants with asthma wheezing episodes only. 
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Other significant findings were reductions in FEV1 and FVC with increase in wheal size 
in the group with no history of asthmatic wheezing. 
Previous studies have demonstrated that the HDM exposure is associated with 
increased risk of asthma, increased bronchial airway responsiveness, and increased in 
both exhaled and nasal fractional nitric oxide. A study found a negative association 
between concentration to Der p group 1 of HDM found in beddings and percent predicted 
FEV1.
44
 However, Langley et al. demonstrated that participants who were exposed and 
sensitized to HDM had a more severe form of asthma in terms of lower percent predicted 
FEV1, higher BHR and FeNO levels than the participants who were only exposed but not 
sensitized.24 Few other studies have reported that increased degree of sensitization was 
associated with severity of asthma.60,62 However, there is no literature on association 
between the wheal size on SPT and pulmonary function parameters. 
Decreased FEV1/FVC and FEF25-75% along with increased FeNO levels in this 
group suggests a possibility of ongoing inflammation of larger as well as smaller airways. 
Asthma can often pose a diagnostic challenge because of inaccurate history of clinical 
symptoms and lack of evidence of airway obstruction on physical examination. Current 
guidelines by National Asthma Education and Prevention Program (NAEPP) to diagnose 
asthma requires at least a partial reversibility in airflow obstruction determined by an 
increase in FEV1 of ≥ 200 mL and ≥ 12 % from baseline measures after bronchodilator 
administration.144 However, Rao et al. have reported that a low FEF25-75% in a group of 
asthmatic children with normal FEV1 could predict severity of asthma.
64 Few other 
studies have also shown reductions in FEF25-75% in individuals allergic specifically to 
HDM but with no wheezing episodes in both asthmatic145 and non-asthmatic children.65 
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We did not find any significant reductions in FEF25-75% in group with no asthmatic 
symptoms, however we did find reductions in FEV1 and FVC. Our findings indicate that 
participants reactive to HDM on SPT but with no history of asthma wheezing attacks may 
still have underlying abnormal pulmonary function.  
Continuous exposure to perennial allergens has been associated with persistence 
of the inflammatory response that may lead to a worsening of respiratory function. Our 
findings related to FeNO were consistent with Moody et al. who reported positive 
correlation between wheal size on HDM SPT and FeNO and nasal nitric oxide levels in 
asymptomatic Pacific Islanders.36 
The subgroup analyses for degree of sensitization showed significant reduction in 
FEV1, FEV1/FVC ratio and FEF25-75% in the group with > 5 mm of wheal diameter 
compared to group with < 3 mm wheal diameter (no sensitization). There were no 
differences in FEV1, FVC and FEV1/FVC ratio for comparisons between 3-5 mm vs < 3 
mm or > 5 mm vs 3-5 mm. However, FEF25-75% was reduced in group with wheal 
diameter 3-5 mm when compared to < 3mm wheal diameter. These results could possibly 
suggest that the effects of HDM sensitivity on larger airways or lung capacity may not 
become evident until the response on SPT reaches 5 mm wheal size but effects on small 
airways can be observed at mild sensitization of 3-5 mm wheal diameter. Although 
Koshak et al. reported increase in severity of asthma with increased degree of 
sensitization to indoor allergens including HDM, there was no information on pulmonary 
function or FeNO levels.62 
There are some limitations to this study. We did not use predicted values for 
pulmonary function parameters and this may limit the generalizability of our results. 
 40 
Although there is plethora of published prediction/ reference equations for spirometric 
indices for European population, the generalizability of these equations is questionable as 
many are based on data collected decades ago on small numbers of subjects specific to a 
set of population and so may affect their applicability to this cohort. However, the new 
reference equations for wider age range and multi-ethnic groups developed as a part of 
Global Lung Function Initiative (GLI) could be used in future studies.127 FEF25-75% is 
known to have highest variability among all pulmonary function measurements. The 
spirometery data used in this study is cross-sectional and therefore could not address the 
variability in FEF25-75%. Finally, sensitivity to HDM is often related with sensitivity to 
other indoor allergens especially cats and dogs. Although we adjusted for sensitivity to 
any allergen other than HDM in our analyses, background correlations could have biased 
the final estimates.  
In conclusion, this study was one of the first to explore the quantitative 
association between immunological response to HDM on SPT and pulmonary function 
parameters. The wheal size on SPT should be considered as a potentially important 
indicator of underlying abnormal pulmonary function even in individuals without asthma 
symptoms. Future research should be focused on longitudinal studies to examine whether 
abnormal pulmonary function related to sensitivity to HDM in non-symptomatic 
individuals have any long term consequences. 
 41 
Table 3.1: Baseline characteristics for adolescents with pulmonary function data at age 18 
years in the Isle of Wight data 
 
Characteristic N % Missing 
Sex 
Boys 395 47.1 
0 
Girls 443 52.9 
HDM result on SPT 
Positive (≥ 3 mm) 242 29.0 
2 
Negative (< 3 mm) 594 71.1 
Degree of sensitization 
> 5 mm 104 12.4 
2 3-5 mm 138 16.5 
< 3 mm 594 71.1 
Duration of positive SPT to HDM 
Since age 4 years 74 30.6 
1 Since age 10 years 65 26.9 
Only at age 18 years 103 42.6 
Asthma wheezing episodes 
Yes 239 28.5 
0 
No 599 71.5 
Current smoking 
Yes (≥ 100 cigarettes) 264 33.0 
38 
No (< 100 cigarettes) 536 67.0 
Atopic sensitization to allergens 
other than HDM 
Yes 262 31.7 
11 
No 565 68.3 
Maternal history of allergy 
Yes 317 38.6 
17 
No 504 61.4 
Paternal history of allergy 
Yes 205 25.2 
23 
No 610 74.9 
Socio-economic status (SES) 
Low 109 13.3 
21 Mid 640 78.3 
High 68 8.3 
Exposure to environmental tobacco 
smoke (ETS) 
Yes 300 39.1 
71 
No 467 60.9 
Use of steroids 
Yes 114 13.6 
0 
No 724 86.4 
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Table 3.2: Average wheal diameter on SPT, anthropometric and pulmonary               
function parameters at age 18 years 
 
Variable N Median Mean SD Missing 
HDM wheal diameter (mm) 836 0 1.7 2.6 2 
Height (cm) 838 170.7 170.9 9.2 0 
Weight (kg) 834 65.5 67.8 13.6 4 
Body Mass Index  834 23.2 23.2 4.3 4 
FEV1 (L) 838 3.9 4.0 0.8 0 
FVC (L) 838 4.5 4.6 0.9 0 
FEV1/FVC Ratio (%) 838 88 87.3 7.2 0 
FEF25-75% (L) 838 4.3 4.4 1.1 0 
FeNO (ppb) 812 22.2 26.4 29.4 26 
SD= Standard deviation, FEV1= Forced expiratory volume in one second,  
FVC= Forced vital capacity, FEF25-75%= Forced expiratory flow at 25-75%,                            
FeNO= Fractional exhaled nitric oxide, ppb= parts per billion 
 
 
 
Table 3.3: Unadjusted average pulmonary function among boys and girls (t-test) 
Pulmonary function 
parameter 
Boys (n=395) Girls (n=443)   
N Mean SE N Mean SE P-value 
FEV1 (L) 395 4.62 0.03 443 3.47 0.02 <.0001 
FVC (L) 395 5.35 0.04 443 3.96 0.03 <.0001 
FEV1/FVC (%) 395 86.55 0.37 443 98.92 0.33 0.0058 
FEF25-75% (L) 395 4.99 0.06 443 3.95 0.04 <.0001 
FeNO (ppb) 381 22.38 1.04 431 15.79 1.03 <.0001 
SE= Standard error                                                                                                                              
Mean and SE estimates are not adjusted for any covariates 
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Table 3.4: Unadjusted average pulmonary function among groups of positive and 
negative SPT for HDM (t-test) 
 
Pulmonary 
function 
parameter  
 HDM SPT=Positive  
(n=242) 
 HDM SPT=Negative 
(n=594) 
  
N Mean SE N Mean SE P-value 
Wheal Diameter 
(mm) 
242 5.37 0.12 594 0.20 0.03 <.0001 
FEV1 (L) 242 4.04 0.05 594 3.99 0.03 0.4529 
FVC (L) 242 4.74 0.06 594 4.56 0.04 0.0103 
FEV1/FVC (%) 242 85.67 0.53 594 87.93 0.27 0.0002 
FEF25-75% (L) 242 4.36 0.08 594 4.48 0.04 0.2228 
FeNO (ppb) 235 34.33 0.02 575 14.52 0.01 <.0001 
Mean and SE estimates are not adjusted for any covariates 
Table 3.5: Unadjusted average pulmonary function among groups of degree of 
sensitization to HDM (ANOVA) 
 
Pulmonary function 
parameter  
≥ 5 mm 
(n=104) 
3-5 mm 
(n=138) 
< 3 mm  
(n=594) 
Mean SE Mean SE Mean SE 
FEV1 (L)  4.04 0.80 4.04 0.07 4.00 0.03 
FVC (L) a 4.81 0.09 4.69 0.08 4..56 0.04 
FEV1/FVC (%) a,b,c 84.46 0.69 85.58 0.60 87.93 0.29 
FEF25-75% (L) a 4.23 0.11 4.46 0.01 4.48 0.05 
FeNO (ppb) a,b,c 42.03 1.07 29.41 1.06 14.52 1.03 
P-value <0.05: a= ≥ 5 mm vs < 3 mm, b= ≥ 5 mm vs 3-5 mm, c= 3-5 mm vs < 3 mm 
ANOVA= Analysis of variance 
Mean and SE estimates are not adjusted for any covariates 
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Table 3.6: Unadjusted average pulmonary function among groups with different             
duration of positive SPT (ANOVA) 
 
Pulmonary function 
parameter  
Since 4 years 
(Early childhood) 
(n=74) 
Since 10 years 
(Pre-adolescence) 
(n=65 
Only at 18 Years 
(Late adolescence) 
(n=103) 
Mean SE Mean SE Mean SE 
FEV1 (L)  3.97 0.09 3.97 0.01 4.14 0.08 
FVC (L) a 4.83 0.11 4.63 0.12 4.75 0.09 
FEV1/FVC (%) a,b,c,d 82.55 0.82 85.84 0.88 87.88 0.69 
FEF25-75% (L) a,b,c 3.99 0.13 4.40 0.14 4.62 0.11 
FeNO (ppb) a,b,d,e,f 44.16 1.08 38.58 1.08 26.70 1.07 
P-value <0.05: a= since 4 years vs negative, b= since 4 years vs only at 10 years,                 
c= since 4 years vs since 10 years, d= since 10 years vs negative, e = since 10 years                 
vs only at 18 years, f = only at 18 years vs negative 
Mean and SE estimates are not adjusted for any covariates 
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Table 3.7: Adjusted linear regression models for pulmonary function and wheal diameter on SPT for                                              
HDM (n=838) 
 
 FEV1 (L) FVC (L) 
 Estimate SE P-value Estimate SE P-value 
Wheal diameter (mm) -0.02 0.01 0.0226 -0.02 0.01 0.0245 
History of wheezing =yes -0.12 0.05 0.0114 -0.13 0.05 0.0135 
Wheal diameter*history of wheezing -0.001 0.01 0.9711 0.04 0.01 0.0024 
 FEV1/FVC (%)
$ FEF25-75% (L) 
 Estimate SE P-value Estimate SE P-value 
Wheal diameter (mm) -0.02 0.14 0.8977 -0.02 0.02 0.2145 
History of wheezing =yes -0.13 0.74 0.8645 -0.14 0.11 0.1805 
Wheal diameter*history of wheezing -0.75 0.19 0.0001 -0.06 0.03 0.0350 
 FeNO (ppb)    
 Estimate SE P-value    
Wheal diameter (mm) 1.10 1.01 <.0001    
History of wheezing =yes 1.09 1.07 0.1932    
Wheal diameter*history of wheezing 1.04 1.02 0.0134    
 FeNO: N=812 
 All models adjusted for height, weight, sex, current smoking, other atopic conditions, maternal and paternal                                                                              
 history of allergy, use of steroids, ETS, SES, and height*sex interaction 
 height*sex interaction not significant  
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Table 3.8: Adjusted linear regression models for pulmonary function and wheal diameter on SPT                                                                     
for HDM stratified by wheezing history 
 
Pulmonary function parameter  
History of wheezing (n=239) No history of wheezing (n=599) 
Estimate SE P-value  Estimate SE P-value  
FEV1(L) -0.02 0.01 0.1177 -0.02 0.01 0.0142 
FVC (L) 0.02 0.01 0.1890 -0.02 0.01 0.0264 
FEV1/FVC (%) $ -0.78 0.19 <.0001 -0.03 0.14 0.8122 
FEF25-75% (L) -0.08 0.03 0.0030 -0.03 0.02 0.1825 
FeNO (ppb) 1.14 1.02 <.0001 1.10 1.01 <.0001 
 All models adjusted for height, weight, sex, current smoking, other atopic conditions, maternal and paternal  
 history of allergy, use of steroids, ETS, SES, and height*sex interaction 
 $height*sex interaction not significant  
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Table 3.9: Adjusted linear regression models for pulmonary function for positive and negative SPT for HDM                                      
(n=838) 
 
 FEV1 (L) FVC (L) 
 Estimate SE P-value Estimate SE P-value 
Wheal diameter (mm) -0.06 0.05 0.2058 -0.08 0.06 0.1395 
History of wheezing =yes -0.13 0.05 0.0116 -0.14 0.06 0.0146 
Wheal diameter*history of wheezing -0.01 0.07 0.8554 0.24 0.08 0.0041 
 FEV1/FVC (%)
$ FEF25-75% (L) 
 Estimate SE P-value Estimate SE P-value 
Wheal diameter (mm) 0.37 0.75 0.622 -0.03 0.11 0.7489 
History of wheezing =yes -0.13 0.76 0.8679 -0.16 0.11 0.1277 
Wheal diameter*history of wheezing -4.54 1.14 <.0001 -0.32 0.16 0.0491 
 FeNO (ppb)    
 Estimate SE P-value    
Wheal diameter (mm) 1.67 1.07 <.0001    
History of wheezing =yes 1.07 1.07 0.3266    
Wheal diameter*history of wheezing 1.37 1.11 0.0021    
 FeNO: N=812 
 All models adjusted for height, weight, sex, current smoking, other atopic conditions, maternal and paternal                                                                              
 history of allergy, use of steroids, ETS, SES, and height*sex interaction 
 height*sex interaction not significant   
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Table 3.10: Differences in least square means between positive and negative SPT for HDM from                                                          
adjusted linear regression models for pulmonary function stratified by wheezing history 
 
Pulmonary function parameter  
History of wheezing (n=239) No history of wheezing (n=599) 
Difference SE P-value  Difference SE P-value  
FEV1(L) -0.08 0.08 0.3288 -0.07 0.05 0.1588 
FVC (L) 0.14 0.09 0.1018 -0.08 0.06 0.1551 
FEV1/FVC (%) $ -4.42 1.18 0.0002 0.29 0.75 0.6962 
FEF25-75% (L) -0.37 0.17 0.0298 -0.05 0.11 0.6535 
FeNO (ppb) 2.19 1.13 <.0001 1.69 1.07 <.0001 
 All models adjusted for height, weight, sex, current smoking, other atopic conditions, maternal and paternal  
 history of allergy, use of steroids, ETS, SES, and height*sex interaction 
 $height*sex interaction not significant 
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Table 3.11: Differences in least square means between groups of different degree of sensitizations for HDM from adjusted linear 
regression models for pulmonary function (n=838) 
 
Pulmonary function  
parameters 
> 5 mm (n=104)  
vs < 3 mm (n=594) 
3-5 mm (n=138)  
vs < 3 mm (n=594) 
> 5 mm (n=104)  
vs < 3-5 mm(n=138) 
Difference SE P-value Difference SE P-value Difference SE P-value 
FEV1 (L) -0.13 0.05 0.0118 -0.02 0.05 0.6232 -0.11 0.06 0.0549 
FVC (L) -0.01 0.06 0.8442 0.02 0.05 0.6903 -0.30 0.07 0.6181 
FEV1/FVC (%) -2.30 0.82 0.0053 -0.67 0.72 0.3508 -1.63 0.90 0.069 
FEF25-75% (L) -0.35 0.17 0.0027 -0.02 0.10 0.8293 -0.33 0.13 0.0098 
FeNO (ppb) 2.25 1.08 <.0001 1.68 1.07 <.0001 1.34 1.08 0.0003 
  FeNO: N=812 
  All models adjusted for height, weight, sex, current smoking, history of asthma wheezing episodes, other atopic                         
  conditions, maternal and paternal history of allergy, use of steroids, ETS and SES  
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Table 3.12: Differences in least square means between groups of different degree of sensitizations for HDM from adjusted                  
linear regression models for pulmonary function (n=838) 
 
Pulmonary function  
parameters 
  
Since age 4 years (n=74) 
vs only at age 18 years (n=103) 
Since age 4 years (n=74) 
vs since age 10 years (n=65) 
Since age 10 years (n=65) 
vs only at age 18 years (n=103) 
Difference SE P-value Difference SE P-value Difference SE P-value 
FEV1 (L) -0.25 0.07 0.0003 -0.15 0.08 0.0554 -0.15 0.08 0.0554 
FVC (L) -0.04 0.08 0.5937 -0.02 0.09 0.7755 -0.02 0.09 0.7755 
FEV1/FVC (%) -4.75 1.08 <.0001 -2.44 1.17 0.0379 -2.44 1.17 0.0379 
FEF25-75% (L) -0.66 0.15 <.0001 -0.49 0.17 0.0032 -0.49 0.17 0.0032 
FeNO (ppb) 1.36 1.10 0.0013 1.08 1.11 0.4647 1.08 1.11 0.4647 
  FeNO: N=812 
  All models adjusted for height, weight, sex, current smoking, history of asthma wheezing episodes, other atopic conditions,        
  maternal and paternal history of allergy, use of steroids, ETS and SES  
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CHAPTER 4 
MATERNAL SMOKING DURING PREGNANCY, ADOLESCENT SMOKING AND 
PULMONARY FUNCTION IN LATE ADOLESCENCE 
Introduction 
Gestational smoking and adolescent smoking are an important public health 
problems. Smedberg et al. reported an overall smoking prevalence of 26 % in pregnant 
women in 15 European countries.72 According to the World Health Organization (WHO), 
the prevalence of tobacco use among adolescents aged 13-15 years is 20 % in boys and 
15 % in girls in Europe.146 Current survey data from United Kingdom indicates that about 
207,000 children aged between 11-15 years starts smoking every year.75 The independent 
effects of both maternal smoking during pregnancy and adolescent smoking on children’s 
respiratory health have been extensively investigated. Evidence from several sources 
show that maternal smoking during pregnancy increased risk of recurrent lower 
respiratory symptoms80-83 and asthma attacks during infancy and early childhood 
years.3,18,84 Many epidemiological studies conducted in adolescents have reported 
reduction in pulmonary function and increased risk of new-onset asthma with increased 
personal smoking by adolescents.13-17 However, the joint effects of both maternal 
smoking during pregnancy and adolescent smoking are less extensively studied. The 
limited information available suggests that adolescent smoking may exacerbate the 
damage already caused to lungs by maternal smoking during pregnancy and may
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 eventually cause greater risk of asthma and pulmonary function deficit.13,93,94 Smoking 
also has differential effects in adolescent males and females. Even though pulmonary 
function decreased with increase in smoking in both boys and girls, girls were found to be 
more vulnerable to the effects of smoking on pulmonary function growth than boys.14,89 
Additionally, a link between maternal smoking during pregnancy and personal smoking 
by adolescents has also been reported. Intergenerational studies by Kandel et al. 
suggested a significant dose related association between both gestational and current 
smoking by mothers and smoking by female offspring during adolescence.91,92 
Both fetal and adolescent period are critical time periods for development of 
lungs. Therefore, any exposure to tobacco smoke during these periods is a form of 
programming which can have long term effects on pulmonary function. Because maternal 
smoking during pregnancy and smoking during adolescence are highly correlated, both 
exposures need to be considered in assessing the adverse effects of tobacco smoke on 
pulmonary function. Adolescent smoking may act as an intervening factor in the pathway 
between maternal smoking during pregnancy and reduction in pulmonary function in 
adolescents. Additionally, maternal smoking during pregnancy has also been associated 
with reduced height and increased obesity in children96-98 which in turn is associated with 
pulmonary function99-102 making height and weight possibly intervening variables. 
The IOW birth cohort offers an opportunity to investigate the independent and 
joint effects of maternal smoking during pregnancy and adolescent smoking on 
pulmonary function in late adolescence. We used pulmonary function data collected in 
participants at 18 years of age to assess the complex relationships between maternal 
smoking during pregnancy and pulmonary function mediated through adolescent 
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smoking, height and weight (both also collected at age 18 years) using path analysis ( 
structural equation models).  
Methods 
Study Population 
Between January 1989 and February 1990 1,536 mothers/child pairs were 
contacted to be enrolled in the IOW birth cohort after obtaining approval from the Isle of 
Wight Local Research Ethics Committee at recruitment. After exclusion of perinatal 
deaths, adoptions, and refusals and obtaining approval from the local research ethics 
committee 1,456 participants were available for follow-up at 1, 2, 4, 10 and 18 years of 
age.130-132  
Exposure 
The main exposures of interests were maternal smoking during pregnancy and 
current personal smoking by adolescents of age 18 years. Birth and obstetric records were 
used to obtain information on maternal smoking during pregnancy. To determine the 
current smoking status children were asked “Do you currently smoke?” at age 18 years. 
Information was also collected on number of cigarettes smoked per day, past smoking 
and duration of smoking. Adolescent smoking was defined as a history of ever smoking 
more than 100 cigarettes. To investigate the independent and joint effects of maternal 
smoking during pregnancy and adolescent smoking we categorized exposure into the 
following mutually exclusive categories: none, exposure to maternal smoking only, 
adolescent smoking only and exposure to both maternal smoking and adolescent 
smoking. This is comparable to a prior categorization used by Sadegnejad et al. to 
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combine exposure to maternal smoking during pregnancy and environmental tobacco 
smoke in the cohort of IOW at age 10 years.134 Pack years were calculated from 
cigarettes smoked per day and duration of smoking and used as main indicator of current 
smoking for path analysis at 18 years of age. 
Outcomes 
Pulmonary function tests were performed using a Koko Spirometer and software 
with a portable desktop device (both PDS Instrumentation, Louisville, KY, USA) to 
measure FVC, FEV1, FEF25-75% and PEFR. Spirometry was performed and evaluated 
according to the American Thoracic Society (ATS) criteria. Children were required to be 
free of respiratory infection for two weeks and not to be taking any oral steroids and were 
advised to abstain from any β-agonist medication for six hours and from caffeine intake 
for at least four hours.132 FeNO was measured (Niox mino, Aerocrine AB, Solna, 
Sweden) according to ATS guidelines.48 Measurements were made in a standardized 
manner with the subject standing without a nose clip; FeNO was measured before 
spirometric testing. Participants were rescheduled if they had clinical symptoms 
consistent with either current infection or a recent (within 2 weeks) asthma exacerbation, 
or had required antibiotics or oral steroids in the preceding 2 weeks.133 We log 
transformed the FeNO values to get a normal distribution. The final estimates were back 
transformed. 
Potential Confounders 
Birth weight, sex, height and weight measured at 18 years, BMI (18 years), 
history of allergic conditions at 18 years (atopy), and socio-economic status (SES) 
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determined at 10 years of age were considered as potential confounders and were 
adjusted in explanatory models. Information on birth weight was obtained from the 
hospital records. Height and weight were measured before the spirometric tests at age 18; 
BMI was calculated. Information on the SES was based on the following three variables: 
(a) the British socioeconomic classes (1–6) derived from parental occupation reported at 
birth; (b) the number of children in the index child’s bedroom (collected at age 4 years); 
and (c) family income at age 10 years.131  
Statistical Analysis 
Of total 1,456 participants 838 participated in spirometric testing at 18 years of 
age. In the initial analyses we used t-tests and analysis of variance (ANOVA) to test the 
differences in pulmonary function among different groups of smoking. Linear regression 
analyses were then used to determine the independent and joint effects of maternal 
smoking during pregnancy and adolescent smoking on pulmonary function. To address 
the issue of missing data on one or more confounders we used multiple imputations 
procedure PROC MI with multivariate normal distribution to generate ten new data sets. 
We used PROC MIXED model to obtain the parameter estimates for each imputed data 
set. Next, we used PROC MIANALYZE to generate valid parameter. The models were 
adjusted for height, weight, birth weight, atopy, ETS and SES. We used backward 
elimination method and selected the confounders that changed the estimates by 10 %. To 
account for the differential effects of lung growth with respect to sex and height we 
introduced interaction term between sex and height in the models.  
As explained earlier, current smoking by adolescents, height and weight possibly 
act as intervening variables in the pathway between maternal smoking during pregnancy 
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and pulmonary function in adolescents. Adjusting on intervening variables in regression 
analyses can disrupt the underlying path. Therefore, we explored these relationships by 
path analysis using Covariance Analysis of Linear Structural Equations. We used Full 
Information Maximum Likelihood (FIML) method to determine parameter estimates 
which addresses the issue of missing values for covariates. Pack years was used as an 
indicator of adolescent smoking in all path analysis models. The adequacy of model fit 
was determined by several statistics: a chi-square p-value > 0.05 if chi-square test statistic 
is close to 0, comparative fit index (CFI) > 0.9, adjusted goodness of fit index (GFI) > 0.9 
and root mean square error of approximation (RMSEA) < 0.06. The data were analyzed 
using the SAS statistical package (version 9.3; SAS Institute, Cary, NC, USA). 
Results 
Out of 838 participants who had spirometry at 18 years of age 443 (52.9 %) were 
girls. Majority of participants belonged to middle social status (78.3 %) based on parental 
occupation, number of children in one bedroom and annual family income. About 41.4 % 
had history of other atopic conditions. The prevalence of adolescent smoking among this 
age group was 33 % and about 20.1 % were exposed to maternal smoking during fetal 
period. About 9.2 % of participants had both smoking exposures (Table 4.1). Average 
anthropometric and pulmonary function measures in the cohort selected for this study are 
presented in Table 4.2. 
On average boys had higher birth weight, height, weight, FEV1, FVC and FEF25-
75% and lower BMI and FEV1/FVC ratio when compared to girls (Table 4.3). These 
estimates were not adjusted for any covariates. The unadjusted estimates for FEV1, 
FEV1/FVC ratio and FEF25-75% were lower in adolescent smokers (> 100 cigarettes) when 
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compared to non-smokers (Table 4.4). Adolescents who were exposed to in-utero 
maternal smoking also showed lower FEV1/FVC ratio and FEF25-75% (Table 4.5). 
Additionally, lower FEV1/FVC ratio and FEF25-75% were observed among adolescents 
who were exposed to both forms of tobacco exposure compared to those who were not 
exposed at all (Table 4.6). Interestingly, we found higher FeNO levels in non-exposed 
adolescents than adolescents exposed to either one or both forms of smoking (Table 4.4 
and 4.6).  
To determine the independent and joint effects of maternal smoking during 
pregnancy and adolescent smoking with pulmonary function, we conducted linear 
regression using four mutually exclusive categories of smoking exposure- maternal 
smoking during pregnancy only, adolescent smoking only, both and none (reference 
category). All the final models were adjusted for height, weight, birth weight, atopy and 
ETS (Table 4.7). Models for FVC and FEV1 were additionally adjusted for interaction 
term sex*height. The results demonstrated individuals who were exposed to both 
maternal smoking and adolescent smoking had lower FEV1/FVC ratio (-1.99 % ± 0.93, p-
value: 0.0328) and FEF25-75% (-0.25 L ± 0.13, p-value: 0.0522) than those who were not 
exposed at all. Group exposed to adolescent smoking only and group exposed to both 
forms of smoking showed higher FeNO levels when compared to reference category (no 
smoking exposure) (Table 4.7). Additionally, FeNO levels were also found to be higher 
in group with both smoking exposures (0.76 ± 1.11 ppb, p-value: 0.0088) when compared 
to the group exposed to maternal smoking only (data not shown in tables). No 
independent effects of either maternal smoking during pregnancy or adolescent smoking 
were observed on any spirometric measures in the total cohort.  
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In stratified analysis, boys did not show reduction in spirometric measures in 
relation to any form of smoking. However there was increase in FEV1 in the group 
exposed to maternal smoking during fetal period when compared to the reference 
category (Table 4.8). In girls we found that both maternal smoking during pregnancy and 
adolescent smoking had independent inverse effects on pulmonary function. While girls 
who were exposed only to maternal smoking during fetal period had reductions in both 
FEV1/FVC ratio and FEF25-75%; girls with exposure only to adolescent smoking showed 
reduction in FEV1 when compared to the group with no exposure. Additionally, there 
were also joint inverse effects of both maternal smoking and adolescent smoking on 
FEV1/FVC ratio and FEF25-75% (Table 4.9). Both boys (except those exposed to maternal 
smoking only) and girls exposed to any form of smoking had higher FeNO levels 
compared to reference category (Table 4.8 and 4.9).  
All path analysis models fulfilled the criteria of model fit. Table 4.10 A presents 
the path coefficients for total, direct and indirect effects of maternal smoking during 
pregnancy on adolescent smoking, birth weight, height and weight at age 18 years in 
boys. In boys maternal smoking during pregnancy had inverse effects on birth weight and 
height at age 18 years and positive effect on adolescent smoking (Table 4.10 A). The path 
analysis assessing the effects of maternal smoking during pregnancy and adolescent 
smoking on pulmonary function was conducted separately in boys and girls and all 
models were adjusted for birth weight, height and weight at 18 years of age and history of 
any atopic conditions, ETS and SES. ETS and SES did not contribute significantly to the 
variance of final path analysis models and their removal from model did not change the 
path coefficients. Path analysis in boys showed that neither maternal smoking nor 
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adolescent smoking had any effects on FEV1, FVC or FEF25-75%, but adolescent smoking 
did have a direct inverse effect on FEV1/FVC ratio (Table 4.11 B). Since maternal 
smoking during pregnancy had positive effect on adolescent smoking possibly effect of 
maternal smoking was carried forward to FEV1/FVC through adolescent smoking (Figure 
4.1). 
On the other hand, in girls maternal smoking during pregnancy had positive 
effects on adolescent smoking and weight at 18 years of age while no effect on either 
birth weight or height at age 18 years (Table 4.10 B). As linear regression models, path 
analysis results also showed that adolescent smoking had direct inverse effect on FEV1 in 
girls and although the maternal smoking did not have any direct effects its effects on 
FEV1 were mediated through adolescent smoking and weight (Table 4.12 A, Figure 4.2). 
Additionally, maternal smoking had both direct and indirect effects mediated through 
weight at age 18 years of age on FEV1/FVC ratio and FEF25-75% but no effects of 
adolescent smoking (Tables 4.12 B, Figure 5.3 and 5.4).  
Discussion 
We studied the IOW birth cohort to assess the independent and joint effects of 
maternal smoking during pregnancy and adolescent smoking on pulmonary function 
during late adolescence. The results of linear regression showed that in boys there were 
no adverse independent or joint effects of maternal smoking during pregnancy and 
adolescent smoking. However, the path analysis suggested that adolescent smoking had 
inverse effects on FEV1/FVC ratio in boys. The path analysis also demonstrated that 
maternal smoking during pregnancy had direct effect on adolescent smoking in both boys 
and girls, thus confirming that offspring of mothers who smoked during pregnancy are 
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more likely to smoke during adolescence. Therefore, even though maternal smoking 
during pregnancy did not have any direct effect on FEV1/FVC ratio in boys, it is possible 
that its adverse effects were mediated through its effects on adolescent smoking.  
In girls both adolescent smoking and maternal smoking had independent as well 
as joint adverse effects on FEV1, FEV1/FVC ratio and FEF25-75%, respectively. Our path 
analysis findings corroborated the results from linear regression. It demonstrated that 
adolescent smoking had direct inverse effect on FEV1 and the effects of maternal 
smoking during pregnancy were mediated through its effects on adolescent smoking and 
weight. Additionally, we also found direct inverse effects of maternal smoking during 
pregnancy on FEV1/FVC and FEF25-75% but no effects of adolescent smoking. Thus, 
although linear regression results suggested that maternal smoking during pregnancy and 
adolescent smoking had joint adverse effects on FEV1/FVC and FEF25-75% in girls, path 
analysis demonstrated these effects were mainly due to maternal smoking during 
pregnancy and adolescent smoking did not contribute significantly to the reduction in 
FEV1/FVC and FEF25-75%. 
Not many studies have investigated the joint effects of maternal smoking during 
pregnancy and adolescent smoking on pulmonary function in adolescents. A study 
conducted by Rizzi et al. in healthy adolescent boys in Milan showed a mild airway 
obstruction in current smokers not exposed to maternal smoking during fetal period and 
deficit in smaller airway function in current passive smokers exposed to maternal 
smoking during fetal period.94 There was however no information on pulmonary function 
among current smokers who were exposed to in-utero maternal smoking. Sherrill et al. 
examined the effects of smoking on lung function in children of age 9 to 15 years in a 
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longitudinal cohort study conducted in New Zealand.95 They reported pulmonary 
function deficit in 9-15 years old children exposed to current parental smoke but no effect 
of either current adolescent smoking or maternal smoking during pregnancy. One 
possible explanation for the discrepancy between our results and results by Sherrill et al. 
may be the differences in the ages of participants. The participants in our study (18 years 
old) were older than Sherrill et al. (9-15 years old) by 3-9 years; the prevalence of 
smoking increases with age. Additionally, only a small number of participants were 
exposed to maternal smoking during pregnancy (n=10); in our study the prevalence of 
maternal smoking during pregnancy was 20.1 % (n=168). Another study by Hayatbakhsh 
et al. conducted in young adults reported that in-utero exposure to maternal smoking was 
associated with a reduction in FEV1 and FEF25–75% in males of 21 years after accounting 
for maternal smoking after pregnancy and smoking by children at age 14 years.93 
However, this study did not consider information on current smoking status by 
participants. Our findings related to differences in boys and girls were comparable to 
those by Holmen et al. and Gold et al.14,89 Both these studies investigated the effects of 
adolescent smoking on pulmonary function after adjusting for passive smoking. Holmen 
et al. in a cohort of 13-18 years old from Norway found that adolescent smoking was 
associated with reduction in pulmonary function only in girls.89 Although Gold et al. 
found lower FEV1/FVC ratio and FEF25-75% in both boys and girls of age 10 -18 years in 
association with adolescent smoking, they found that girls were more vulnerable to 
adverse effects of smoking and had lower growth of pulmonary function than boys.14 Our 
findings related to maternal smoking during pregnancy were partially comparable to a 
study by Hollams et al. who reported reduction in FEV1/FVC ratio and FEF25-75% in 
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association with maternal smoking during pregnancy in current adolescent non-
smokers.147 
Although the unadjusted estimates of FeNO were lower in those exposed to either 
form of smoking (Table 4.4, 4.5 and 4.6) the adjusted linear regression estimates 
demonstrated higher FeNO levels in both boys and girls who were exposed either to 
maternal smoking during fetal period or current smoking or both (Tables 4.8 and 4.9). 
Previous studies have reported increased FeNO levels in infants and young children who 
were exposed to maternal smoking during pregnancy.148,149 To our knowledge no study 
has examined this relationship in adolescents. 
The underlying pathophysiological mechanisms of adverse effects of personal 
smoking are well documented. Persistent exposure to smoking causes inflammation and 
epithelial changes in bronchial tissues which leads to secretory congestion and fibrosis 
causing remodeling of airways and destruction of alveoli resulting in loss of gas 
exchange.77 Although there have been no histological study describing the patho-
physiological effects of maternal smoking on the airway development during fetal period 
in humans; one can hypothesize that smoking will adversely affect the development of 
lungs during the gestational period as a result of blood flow restriction to the placenta due 
to nicotine induced vasoconstriction, poor nutritional status of the mother associated with 
the anorexigenic effect of nicotine and carbon monoxide exposure.78 An animal model 
presented by Rehan et al. to study the effects of maternal smoking on fetal lung 
development showed that in-utero exposure to tobacco smoke alters the normal 
homeostatic epithelial-mesenchymal interaction in the developing alveolus, resulting in 
production of myofibroblasts.79 Myofibroblasts contribute to the formation of fibrosis in 
 63 
larger as well as smaller airways and is a common finding in asthma and chronic lung 
disease.79 Previous studies have also shown an association between maternal smoking 
during pregnancy and higher FVC in children.150-152 Studies have suggested that maternal 
smoking during pregnancy or exposure to parental smoking during early childhood may 
cause disproportional growth of lung parenchyma and airways known as dysnaptic 
growth of lungs in children.69,151,153,154 Our findings were different from previous studies, 
we found increased FEV1 in boys in relation to maternal smoking during pregnancy. It is 
possible that maternal smoking during pregnancy disrupted the process of normal lung 
growth and altered the pattern of growth of the airways in relation to lung size.  
There are some limitations to our study. Because of negative attitude towards 
smoking during pregnancy the self-reported information on smoking during pregnancy 
was probably underestimated and it was not validated by objective measurements. Under-
reporting of smoking prevalence may bias our estimates for maternal smoking during 
pregnancy towards the null. We also did not use predicted values for pulmonary function 
parameters and this may limit the interpretation of our results in clinical settings. Our 
modeling strategy with linear regression for pulmonary function may have introduced 
some errors in our estimates. Maternal smoking during pregnancy affects birth weight 
which in turn has independent association with pulmonary function.155,156 Therefore, 
adjusting on birth weight in linear regression may have introduced bias. However, use of 
path analysis allowed us to include birth weight as mediating factor in the explanatory 
models which helped disentangle the complex relationship between numerous 
determinants of pulmonary function. Additionally, in linear regression we had small 
sample size in four smoking exposure categories stratified by sex but this was not a 
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problem in path analysis as maternal smoking during pregnancy and adolescent smoking 
were considered as two independent factors. 
In conclusion our findings suggest that maternal smoking during pregnancy has 
an adverse association with adolescent smoking in offspring. The joint effects of maternal 
smoking during pregnancy and adolescent smoking may be responsible for larger deficit 
in pulmonary function than the independent effect of either exposure. However, these 
finding were significant only in girls. The results of the path analysis deepened our 
understanding of relationships between various determinants of pulmonary function. The 
increased FeNO levels and reduction in FEV1/FVC and FEF25-75% values found in girls 
suggest that tobacco smoke leads to chronic inflammation and remodeling in small as 
well as larger airways. These data demonstrate that not only tobacco exposure has 
differential inverse effects on pulmonary function among adolescent boys and girls, but 
maternal smoking during pregnancy has a measurable adverse effect on the pulmonary 
function which is independent of any direct use of cigarettes by adolescents. These 
findings are especially important because lower pulmonary function during adolescence 
may possibly lead to chronic obstructive pulmonary disease and small airway disease in 
adulthood. Our results confirm the need of intervention strategies of tobacco cessation in 
adolescents and women of reproductive age. Furthermore, reduction in maternal smoking 
during pregnancy may not only reduce the burden of chronic respiratory diseases in the 
long term but may also reduce the burden of smoking in the adolescents. 
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Table 4.1: Baseline characteristics for adolescents with pulmonary function data                  
at age 18 years in the Isle of Wight data  
 
Characteristic    N % Missing 
Sex  
Boys 395 47.1 
0 
Girls 443 52.9 
Maternal smoking  
during pregnancy  
Yes 168 20.1 
4 
No 666 79.9 
Adolescent smoking  
Yes (≥ 100 cigarettes) 264 33.0 
38 
No (< 100 cigarettes) 536 67.0 
Maternal smoking  
during pregnancy  
+ adolescent smoking 
  
Both 73 9.2 
42 
Maternal smoking  
during pregnancy only 
86 10.8 
Adolescent smoking 
only 
189 23.7 
None 448 56.3 
Environmental 
tobacco smoke (ETS)  
Yes 300 39.1 
71 
No 467 60.9 
History of any atopic  
condition  
Yes 343 41.4 
10 
No 485 58.6 
Socio-economic  
status (SES)  
  
Lower 109 13.3 
21 Middle 640 78.3 
Higher 68 8.3 
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Table 4.2: Average anthropometric and pulmonary function                                   
parameters at age 18 years 
 
  N Mean  Median  SD Missing 
Birth weight (kg) 825 3.41 3.42 0.51 13 
Height (cm) 838 170.88 170.70 9.17 0 
Weight (kg) 834 67.79 65.50 13.60 4 
BMI  834 23.21 22.15 4.33 4 
FEV1 (L) 838 4.01 3.91 0.78 0 
FVC (L) 838 4.61 4.47 0.93 0 
FEV1/FVC (%) 838 87.28 88.00 7.16 0 
FEF25-75% (L) 838 4.44 4.32 1.14 0 
FeNO (ppb) 822 26.27 16.00 29.28 0 
SD= Standard deviation, FEV1= Forced expiratory volume in one second,  
FVC= Forced vital capacity, FEF25-75%= Forced expiratory flow at 25-75%,                            
FeNO= Fractional exhaled nitric oxide, ppb= parts per billion
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Table 4.3: Comparison of smoking exposure, anthropometric and pulmonary function 
measures among boys and girls at age 18 years (t-test) 
 
Variable 
Boys Girls 
N % N % 
Maternal smoking  
during pregnancy  
Yes 75 19.1 93 21.0 
No 317 80.9 349 79.0 
Adolescent 
smoking  
Yes (≥ 100 cigarettes) 113 30.1 151 35.6 
No (< 100 cigarettes) 263 69.9 273 64.4 
Maternal smoking  
during pregnancy  
+ adolescent 
smoking 
  
Both 32 8.6 41 9.7 
Maternal smoking  
during pregnancy only 
42 11.3 44 10.4 
Adolescent smoking only 80 21.4 109 25.8 
None 219 58.7 229 54.1 
 Variable 
Boys Girls  
N Mean SE N Mean  SE P-value 
Birth weight (kg) 389 3.48 0.03 436 3.36 0.02 0.0009 
Height (cm) 395 177.8 0.33 443 164.7 0.29 <.0001 
Weight (kg) 394 71.22 0.64 440 64.71 0.65 <.0002 
BMI  394 22.51 0.19 440 23.84 0.23 <.0003 
FEV1 (L) 395 4.62 0.03 443 3.47 3.47 <.0001 
FVC (L) 395 5.35 0.04 443 3.96 0.03 <.0001 
FEV1/FVC (%) 395 86.55 0.37 443 87.92 0.33 0.0058 
FEF25-75% (L) 395 4.99 0.06 443 3.95 0.04 <.0001 
FeNO (ppb) 387 22.26 1.04 435 15.74 1.03 <.0001 
SE= Standard error 
Mean and SE estimates are not adjusted for any covariates
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Table 4.4: Unadjusted average pulmonary function stratified by adolescent                    
smoking status (t-test) 
 
Pulmonary 
function parameter 
Smoker 
(>100 cigarettes) 
(n=264) 
Non-smoker 
(≤ 100 cigarettes) 
n=(536) 
  
  Mean SE Mean  SE P-value 
FEV1 (L) 3.91 0.05 4.06 0.03 0.015 
FVC (L) 4.55 0.06 4.65 0.04 0.1571 
FEV1/FVC (%) 86.49 0.45 87.68 0.31 0.0275 
FEF25-75% (L) 4.29 0.07 4.51 0.05 0.0083 
FeNO (ppb) 15.59 11.05 19.97 1.03 <0.001 
FeNO: smoker=260, non-smoker=524 
Mean and SE estimates are not adjusted for any covariates 
 
Table 4.5: Unadjusted average pulmonary function stratified by                                    
maternal smoking during pregnancy (t-test) 
 
Pulmonary 
function 
parameter  
Maternal smoking during pregnancy  
Yes (n=168)  No (n=666)   
  Mean SE Mean  SE P-value 
FEV1 (L) 3.96 0.06 4.02 0.03 0.3399 
FVC (L) 4.61 0.07 4.61 0.04 0.9642 
FEV1/FVC (%) 86.15 0.56 87.55 0.28 0.0236 
FEF25-75% (L) 4.28 0.09 4.48 0.04 0.0424 
FeNO (ppb) 22.93 2.20 27.15 1.16 0.0988 
FeNO: Maternal smoking during pregnancy - yes=168, no=653 
Mean and SE estimates are not adjusted for any covariates
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Table 4.6: Unadjusted average pulmonary function stratified by combined smoking 
exposure status (ANOVA) 
 
Pulmonary 
function 
parameter 
Maternal + 
adolescent 
smoking 
(n=73) 
Only maternal 
smoking during 
pregnancy 
(n=86) 
Only adolescent 
smoking 
(n=189) 
None (n=448) 
  Mean SE Mean  SE Mean  SE Mean  SE 
FEV1 (L) 3.87 0.09 4.07 0.08 3.94 0.06 4.05 0.04 
FVC (L) 4.54 0.11 4.72 0.10 4.56 0.07 4.63 0.04 
FEV1/FVC (%)* 85.73 0.84 86.57 0.78 86.74 0.52 87.90 0.34 
FEF25-75% (L)* 4.14 0.13 4.44 0.12 4.35 0.08 4.52 0.05 
FeNO (ppb)* 19.40 3.46 26.22 3.16 24.04 2.13 27.88 1.39 
FeNO: Maternal + adolescent smoking=71, only maternal smoking during pregnancy=85, only 
adolescent smoking=187, none=437 
*= significant differences in Maternal + adolescent smoking vs none 
ANOVA= Analysis of variance
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Table 4.7: Joint effects of maternal smoking during pregnancy and                             
adolescent smoking on pulmonary function in total cohort (n=838) 
 
Pulmonary function parameter Difference 
† SE P-value 
FEV1 (L) $       
Maternal + adolescent smoking -0.05 0.06 0.4379 
Maternal smoking only 0.05 0.06 0.3724 
Adolescent smoking only -0.04 0.04 0.2662 
FVC (L) $       
Maternal + adolescent smoking 0.05 0.07 0.4873 
Maternal smoking only 0.11 0.06 0.0903 
Adolescent smoking only 0.01 0.04 0.8666 
FEV1/FVC (%)       
Maternal + adolescent smoking -1.99 0.93 0.0328 
Maternal smoking only -1.06 0.87 0.2237 
Adolescent smoking only -1.05 0.60 0.0822 
FEF25-75% (L)       
Maternal + adolescent smoking -0.25 0.13 0.0522 
Maternal smoking only -0.05 0.12 0.689 
Adolescent smoking only -0.10 0.09 0.247 
FeNO (ppb)*       
Maternal + adolescent smoking 0.68 1.09 <.0001 
Maternal smoking only 0.91 1.09 0.2296 
Adolescent smoking only 0.81 1.06 0.0002 
FeNO: n=822  
Reference category= none  
All models are adjusted for birth weight, sex, height, weight, history of                                           
any atopic condition, environmental tobacco smoke (ETS)  
† Differences in least squares means from linear regression models 
$ Models for FVC and FEV1 are additionally adjusted for interaction term                                 
sex*height  
* Difference was also significant between both vs maternal smoking only                                       
0.76 ± 1.11 (p-value 0.0088) 
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Table 4.8: Joint effects of maternal smoking during pregnancy and                         
adolescent smoking on pulmonary function in boys (n=395) 
 
Pulmonary function parameter Difference 
† SE P-value 
FEV1 (L)       
Maternal + adolescent smoking 0.04 0.10 0.6722 
Maternal smoking only 0.21 0.09 0.0245 
Adolescent smoking only 0.03 0.07 0.6687 
FVC (L)       
Maternal + adolescent smoking 0.08 0.12 0.4952 
Maternal smoking only 0.18 0.10 0.0897 
Adolescent smoking only 0.12 0.07 0.1062 
FEV1/FVC (%)       
Maternal + adolescent smoking -0.60 1.47 0.6835 
Maternal smoking only 1.28 1.32 0.3323 
Adolescent smoking only -1.41 0.94 0.1327 
FEF25-75% (L)       
Maternal + adolescent smoking -0.05 0.23 0.8175 
Maternal smoking only 0.29 0.20 0.1545 
Adolescent smoking only -0.08 0.15 0.5666 
FeNO (ppb)*       
Maternal + adolescent smoking 0.66 1.15 0.0029 
Maternal smoking only 1.04 1.14 0.7693 
Adolescent smoking only 0.74 1.09 0.001 
FeNO: n=387 
Reference category= none 
† Differences in least squares means from linear regression models 
All models are adjusted for birth weight, height, weight, history of any                                         
atopic condition, ETS  
* Differences were also significant between both vs maternal smoking                                              
only 0.63 ± 1.18 (p-value 0.0061) and maternal smoking only vs adolescent                              
smoking only 1.38 ± 1.14 (p-value=0.0156) 
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Table 4.9: Joint effects of maternal smoking during pregnancy and                          
adolescent smoking on pulmonary function in girls (n=443) 
 
Pulmonary function parameter Difference 
† SE P-value 
FEV1 (L)       
Maternal + adolescent smoking -0.11 0.07 0.1052 
Maternal smoking only -0.08 0.07 0.1983 
Adolescent smoking only -0.10 0.05 0.0221 
FVC (L)       
Maternal + adolescent smoking 0.02 0.07 0.8159 
Maternal smoking only 0.03 0.07 0.6453 
Adolescent smoking only -0.09 0.05 0.0892 
FEV1/FVC (%)       
Maternal + adolescent smoking -2.84 1.20 0.0182 
Maternal smoking only -2.88 1.16 0.0131 
Adolescent smoking only -0.79 0.79 0.313 
FEF25-75% (L)       
Maternal + adolescent smoking -0.37 0.15 0.0127 
Maternal smoking only -0.32 0.14 0.0289 
Adolescent smoking only -0.12 0.10 0.239 
FeNO (ppb)*       
Maternal + adolescent smoking 0.72 1.12 0.0031 
Maternal smoking only 0.82 1.11 0.0554 
Adolescent smoking only 0.86 1.08 0.0442 
FeNO: n=435 
Reference category= none 
† Differences in least squares means from linear regression models 
All models are adjusted for birth weight, height, weight, history of any                                         
atopic condition, ETS 
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Table 4.10 A: The standardized direct, indirect and total effects of maternal smoking during pregnancy on birth weight,                
height, weight and adolescent smoking in boys (n=395) 
 
Variables Total Direct Indirect 
 Estimate SE P-value Estimate SE P-value Estimate SE P-value 
Birth weight -0.23 0.05 <.0001 -0.23 0.05 <.0001    
Height at 18 years -0.13 0.05 0.0071 -0.09 0.05 0.0459 -0.04 0.02 0.0977 
Weight at 18 years 0.02 0.05 0.6587 0.04 0.05 0.3933 -0.02 0.01 0.0921 
Adolescent smoking (pack years) 0.21 0.05 <.0001 0.21 0.05 <.0001    
Effect of maternal smoking during pregnancy on each variable is adjusted by other covariates explanatory models.  
Goodness of Fit Criteria: Chi-squared test statistic=1.85, p-value 0.9326; AGFI=0.9999; CFI=1; RMSEA=0
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Table 4.10 B: The standardized direct, indirect and total effects of maternal smoking during pregnancy on birth weight,                
height, weight and adolescent smoking in girls (n=443) 
 
 Variables Total  Direct  Indirect  
  Estimate SE P-value  Estimate SE P-value  Estimate SE P-value  
Birth weight -0.05 0.05 0.2925 -0.05 0.05 0.2925       
Height at 18 years -0.03 0.05 0.5115 -0.08 0.04 0.0861 0.05 0.02 0.0222 
Weight at 18 years 0.18 0.05 0.0001 0.18 0.05 <.0001       
Adolescent smoking (pack years) 0.26 0.05 <.0001 0.26 0.05 <.0001 -0.01 0.01 0.3099 
Effect of maternal smoking during pregnancy on each variable is adjusted by other covariates explanatory models.  
Goodness of Fit Criteria: Chi-squared test statistic=9.24, p-value 0.1601; AGFI=0.9997; CFI=0.9877; RMSEA=0.035
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Table 4.11 A: The standardized direct, indirect and total effects of maternal smoking during pregnancy and adolescent smoking     
along with other covariates on FEV1 and FVC in boys (n=395) 
 
FEV1 
 Variables Total Direct Indirect  
 Estimate SE P-value  Estimate SE P-value  Estimate SE P-value  
Maternal smoking during pregnancy 0.003 0.05 0.9536 0.10 0.04 0.0274 -0.09 0.03 0.0034 
Adolescent smoking (pack years) -0.04 0.04 0.3854 -0.04 0.04 0.3854       
Birth weight 0.23 0.05 <.0001 0.10 0.04 0.0204 0.13 0.03 <.0001 
Height 0.51 0.04 <.0001 0.51 0.04 <.0001       
Weight 0.25 0.05 <.0001 0.06 0.04 0.1512 0.19 0.03 <.0001 
Atopy  -0.07 0.04 0.0748 -0.07 0.04 0.0748       
FVC 
Maternal smoking during pregnancy 0.003 0.05 0.9585 0.06 0.04 0.1398 -0.06 0.03 0.0794 
Adolescent smoking (pack years) 0.05 0.04 0.2142 0.05 0.04 0.2142       
Birth weight 0.17 0.05 0.0010 0.02 0.04 0.5935 0.14 0.03 <.0001 
Height 0.53 0.04 <.0001 0.53 0.04 <.0001       
Weight 0.36 0.04 <.0001 0.16 0.04 0.0002 0.19 0.02 <.0001 
Atopy  -0.03 0.04 0.4194 -0.03 0.04 0.4194       
Model Fit Criteria: FEV1- Chi-squared test statistic=1.85, p-value 0.9326; AGFI=0.9999; CFI=1; RMSEA=0 
FVC- Chi-squared test statistic=1.81, p-value 0.9364; AGFI=0.9999; CFI=1; RMSEA=0 
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Table 4.11 B: The standardized direct, indirect and total effects of maternal smoking during pregnancy and adolescent smoking      
along with other covariates on FEV1/FVC and FEF25-75% in boys (n=395) 
 
FEV1/FVC 
 Variables Total Direct Indirect 
 Estimate SE P-value  Estimate SE P-value  Estimate SE P-value  
Maternal smoking during pregnancy 0.01 0.05 0.7996 0.06 0.05 0.2611 -0.05 0.02 0.0281 
Adolescent smoking (pack years) -0.12 0.05 0.0176 -0.12 0.05 0.0176       
Birth weight 0.08 0.05 0.1070 0.11 0.05 0.0396 -0.02 0.02 0.1100 
Height -0.04 0.05 0.4531 -0.04 0.05 0.4531       
Weight -0.17 0.05 0.0006 -0.15 0.05 0.0037 -0.02 0.02 0.4546 
Atopy  -0.06 0.05 0.2399 -0.06 0.05 0.2399       
FEF25-75% 
Maternal smoking during pregnancy -0.01 0.05 0.8627 0.07 0.05 0.1972 -0.07 0.02 0.0007 
Adolescent smoking (pack years) -0.09 0.05 0.0877 -0.09 0.05 0.0877       
Birth weight 0.18 0.05 0.0004 0.13 0.05 0.0136 0.05 0.02 0.0012 
Height 0.22 0.05 <.0001 0.22 0.05 <.0001       
Weight 0.06 0.05 0.1926 -0.02 0.05 0.7494 0.08 0.02 0.0002 
Atopy  -0.05 0.05 0.3169 -0.05 0.05 0.3169       
Model Fit Criteria: FEV1/FVC- Chi-squared test statistic=1.86, p-value 0.9324; AGFI=0.9999; CFI=1; RMSEA=0 
FEF25-75%- Chi-squared test statistic=1.85, p-value 0.9327; AGFI=0.9999; CFI=1; RMSEA=0 
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Table 4.12 A: The standardized direct, indirect and total effects of maternal smoking during pregnancy and adolescent smoking     
along with other covariates on FEV1 and FVC in girls (n=443) 
 
FEV1 
 Variables Total Direct Indirect  
 Estimate SE P-value  Estimate SE P-value  Estimate SE P-value  
Maternal smoking during pregnancy -0.06 0.05 0.2296 -0.03 0.04 0.5035 -0.03 0.03 0.3237 
Adolescent smoking (pack years) -0.10 0.04 0.0139 -0.10 0.04 0.0139       
Birth weight 0.16 0.05 0.0007 0.03 0.04 0.4623 0.13 0.03 <.0001 
Height 0.48 0.04 <.0001 0.48 0.04 <.0001       
Weight 0.23 0.05 <.0001 0.08 0.04 0.0636 0.15 0.02 <.0001 
Atopy  -0.04 0.04 0.3751 -0.04 0.04 0.3751       
FVC 
Maternal smoking during pregnancy 0.05 0.05 0.3280 0.07 0.04 0.0685 -0.03 0.03 0.3985 
Adolescent smoking (pack years) -0.12 0.04 0.0021 -0.12 0.04 0.0021       
Birth weight 0.21 0.05 <.0001 0.07 0.04 0.0920 0.14 0.03 <.0001 
Height 0.51 0.04 <.0001 0.51 0.04 <.0001       
Weight 0.29 0.04 <.0001 0.14 0.04 0.0010 0.16 0.02 <.0001 
Atopy  -0.003 0.04 0.9458 -0.003 0.04 0.9458       
Model Fit Criteria: FEV1- Chi-squared test statistic=9.25, p-value 0.1601; AGFI=0.9997; CFI=0.9877; RMSEA=0.035 
FVC- Chi-squared test statistic=9.16, p-value 0.165; AGFI=0.9997; CFI=0.99; RMSEA=0.03545
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Table 4.12 B: The standardized direct, indirect and total effects of maternal smoking during pregnancy and adolescent smoking      
along with other covariates on FEV1/FVC and FEF25-75% in girls (n=443) 
 
FEV1/FVC 
 Variables Total Direct Indirect 
 Estimate SE P-value  Estimate SE P-value  Estimate SE P-value  
Maternal smoking during pregnancy -0.17 0.05 0.0003 -0.17 0.05 0.0006 0.00 0.02 0.9572 
Adolescent smoking (pack years) 0.03 0.05 0.4864 0.03 0.05 0.4864       
Birth weight -0.09 0.05 0.0536 -0.06 0.05 0.2492 -0.03 0.01 0.0125 
Height -0.08 0.05 0.1158 -0.08 0.05 0.1158       
Weight -0.11 0.05 0.0181 -0.09 0.05 0.0768 -0.02 0.02 0.1245 
Atopy  -0.07 0.05 0.1448 -0.07 0.05 0.1448       
FEF25-75% 
Maternal smoking during pregnancy -0.14 0.05 0.0032 -0.14 0.05 0.0037 0.00 0.02 0.8554 
Adolescent smoking (pack years) -0.01 0.05 0.7750 -0.01 0.05 0.7750       
Birth weight 0.04 0.05 0.4166 -0.01 0.05 0.8468 0.05 0.02 0.0015 
Height 0.16 0.05 0.0016 0.16 0.05 0.0016       
Weight 0.11 0.05 0.0251 0.06 0.05 0.2340 0.05 0.02 0.0038 
Atopy  -0.06 0.05 0.2314 -0.06 0.05 0.2314       
Model Fit Criteria: FEV1/FVC- Chi-squared test statistic=9.12, p-value 0.1657; AGFI=0.9998; CFI=0.978; RMSEA=0.0343 
FEF25-75%- Chi-squared test statistic=9.23, p-value 0.1612; AGFI=0.9997; CFI=0.9773; RMSEA=0.0348
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Figure 4.1: Analytical path model exploring the standardized direct effects of maternal smoking during pregnancy and adolescent 
smoking on FEV1/FVC in boys (path coefficients from Table 4.10 A and 4.11 B) 
 
The path coefficients represented by solid arrows are direct effects. The coefficients for covariates with non-significant total effects are not 
depicted in this diagram.  
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Figure 4.2: Analytical path model exploring the standardized direct and indirect effects of maternal smoking during pregnancy and 
adolescent smoking on FEV1 in girls (path coefficients from Table 4.10 B and 4.12 A) 
 
The path coefficients represented by solid arrows are direct effects while those represented by dashed arrows are indirect effects. The coefficients 
for covariates with non-significant total effects are not depicted in this diagram.  
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Figure 4.3: Analytical path model exploring the standardized direct and total effects of maternal smoking during pregnancy and 
adolescent smoking on FEV1/FVC in girls (path coefficients from Table 4.10 B and 4.12 B) 
 
 
The path coefficients represented by solid arrows are direct effects while those represented by dashed and dotted arrows (                   ) are total 
effects. The coefficients for covariates with non-significant total effects are not depicted in this diagram. 
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Figure4.4: Analytical path model exploring the standardized direct and indirect effects of maternal smoking during pregnancy and 
adolescent smoking on FEF25-75% in girls (path coefficients from Table 4.10 B and 4.12 B) 
 
 
The path coefficients represented by solid arrows are direct effects while those represented by dashed arrows are indirect effects. The coefficients 
for covariates with non-significant total effects are not depicted in this diagram.    
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CHAPTER 5 
EXPOSURE TO DICHLORODIPHENYL DICHLOROETHENE (DDE) AND 
CHILDHOOD PULMONARY FUNCTION 
Introduction 
Dichlorodiphenyl dichloroethene (DDE) is principal metabolite of 
dichlorodiphenyl trichloroethane (DDT) which is a synthetic chemical belonging to 
organochlorine chemicals family and is recognized as persistent organic pollutants.106 
DDT was a widely used insecticide until it was banned in most developed countries by 
the end of 1980s.105,106 However, it is still largely used in developing countries for 
malaria control and in agriculture. Because of its lipophilic properties and very long half-
life DDE persists in environment in all forms of life. 105,106 Humans are exposed to DDE 
through food chain which accumulates in adipose tissue, bloodstream and breast.105,106 
Evidence from longitudinal studies has shown that both prenatal and postnatal 
exposure to DDE leads to reduction in growth of height and increase in BMI during 
childhood.113,114,157 Not only the anti-androgenic properties of DDE are known to 
interfere with puberty reducing the age of menarche,121 but high levels of DDE have also 
been found in girls with precocious puberty.157 DDE is also considered to alter both 
cellular and humoral immunity with increased production of cytokines and nitric 
oxide.108-111 Prenatal exposure to DDE has also been linked with respiratory disorders
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 like lower respiratory tract infections, episodes of wheezing, otitis media and increased 
risk of asthma in early childhood.20,123-126 
In children and adolescents, average pulmonary function growth varies greatly 
with height, weight, sex and age of pubertal growth spurt.128-130 Exposure to DDE may 
not only disrupts growth of height and weight in children, but immunological responses 
to persistent exposure to DDE may also alter physiology of airways through remodeling 
during this critical period of lung growth. To date, no study has ever investigated 
relationship between burden of DDE and pulmonary function in children. We 
hypothesized that DDE exposure affect pulmonary function in childhood, directly or 
indirectly via height and weight in addition to its immunological role. To assess these 
complex relationships we used path analysis approach (structural equation models). Path 
analysis is an extension of multiple regression and it offers flexibility to generate 
estimates for hypothesized causal associations between sets of variables. Path analysis 
also allows the use of intervening or mediating variables in the explanatory models which 
ultimately provide the direct, indirect and total effects of each variable on the outcome 
which can be used to develop causal path diagram. 
An environmental epidemiologic study was conducted in central Germany, to 
investigate the effects of persistent body burden of polychlorinated biphenyls (PCBs) and 
DDE on health of children.114 In addition to showing a small reduction in height in 
girls,114 other results from this study showed that DDE was related with increased total 
IgE and asthma.125,158 In this research paper, our aim is to investigate the effects of 
persistent DDE exposure on childhood pulmonary function in this study. We provide 
results from repeated measurement analysis followed by results from path analysis.  
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Methods 
Study Population 
We used data from a longitudinal study conducted in the south of the federal state 
of Hesse, in central Germany, between 1994 and1997. Children were recruited from 3 
different regions which were located around industrial waste incinerator among other 
industries (e.g., chemical plants). One is in the Rhine Valley, with low mountains on both 
sides, within a 15-km radius around an industrial waste incinerator and is also used 
intensively for vegetable production. A second region, also industrial and agricultural, is 
20 km north of the incinerator area. The third region is located in low mountains (about 
400 m above sea level).114 After obtaining permits from the Data Protection Agency of 
the State of Hamburg, Germany, from the Ministry of Cultural Affairs of Hesse, 
Germany, and from the local school committees, parents of 1091 second grade school 
children in 18 townships were asked to participate in this study. Informed consent, 
according to the requirements of the Ethical Committee of the Board of Physicians and 
the Data Protection Agency of the State of Hamburg, was obtained from all participating 
parents. Parents were asked to let their children participate in phlebotomy only when 
passive smoking in the private household had not exceeded 10 cigarettes per day in the 
previous 12 months. Children and their parents participated in the 3 repeated surveys 
(December 1994–April 1995, January to May1996, January to June 1997).114  
Organochlorines in Blood  
A blood sample was taken as part of the first visit. DDE concentrations were 
determined from 5-mL samples of whole blood by performing high-resolution gas 
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chromatography (HRGC, Model 3400, Varian, Gloucester, Mass) with a 63Ni electron 
capture detector at the Institute of Toxicology, University of Kiel, Germany. The 
detection limit was 0.02 µg/L for DDE. In addition, reliability was tested with gas 
chromatography– mass spectometry. The laboratory successfully participated in 
nationwide interlaboratory quality assessments for DDE and PCB determinations.114 
Pulmonary Function  
Pulmonary function tests were conducted at 8, 9 and 10 years of age using a 
Masterscope (Software Release 4.0; Erich Jaeger, Würzburg, Germany). The instrument 
was calibrated daily and each child performed two forced expiratory maneuvers 
according to the American Thoracic Society (ATS) guidelines in standing position 
wearing a nose clip. Two flow/volume curves were accepted as reproducible if the 
difference between FVC measurements was ≤ 5%. The highest FVC and FEV1 values 
were then selected for statistical analysis.  
Covariates 
Self-administered questionnaires were used in the survey. Information was 
collected on child’s age, birth weight, birth order, maternal and paternal education, 
maternal and paternal height, smoking during pregnancy, and breast-feeding duration. 
Height and weight were measured for each child in 3 consecutive examinations 1 year 
apart (ages of 8, 9, and 10 years) before each spirometric examination. Environmental 
tobacco smoke (ETS) was assessed as smoking in the child’s home in the previous 12 
months (per day: no cigarettes, 1-10 cigarettes, 11-20 cigarettes, 20-30 cigarettes, >30 
cigarettes).114  
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Statistical Analysis 
For the purpose of this research paper, we used pulmonary function data only 
from those children who had information on blood levels of DDE either in 1995 or 1997. 
As DDE exposure was not measured in 1996, for this year we selected children who had 
PFT done either in 1995 or 1997 with information on DDE exposure. The final data set 
contained 1000 observations with 344 participants. We imputed values for DDE exposure 
in 1996 based on the values in years 1995 and 1997 using multiple imputation methods. 
Multiple imputations were also used for missing data on one or more confounders. As a 
first step, linear correlations between DDE exposure and height, weight, FEV1, FVC and 
FEV1/FVC were determined using PROC CORR for years 1995 and1997. Next we used 
linear mixed models (PROC MIXED) on imputed data sets to assess the association 
between blood levels of DDE and repeated pulmonary function measurements. 
Compound symmetry covariance structure matrix was selected based on lowest Akaike 
information criteria and the Bayesian Schwarz information criterion after considering 
unstructured, compound symmetry and autoregressive covariance structure matrices. All 
models were adjusted for age, sex, birth weight, breast feeding duration, height, weight, 
smoking during pregnancy, parental history of asthma and ETS. We selected those 
covariates for the final model which changed the pulmonary function estimates for DDE 
exposure by 10 %. To account for differential association between height and pulmonary 
function in boys and girls we included interaction terms of height with sex. Finally all 
results were combined and valid statistical inferences were generated using 
MIANALYZE procedure. 
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Further, we explored the relationship between DDE exposure, height, weight and 
pulmonary function in childhood by path analysis using the Covariance Analysis of 
Linear Structural Equations procedure. However, since DDE exposure was not measured 
in 1996 even after using Full Information Maximum Likelihood (FIML) method which 
takes into consideration the missingness the final path models did not converge for 
repeated measures data. Therefore, we used two separate path analysis model for cross-
sectional data from years 1995 and 1997. However, we included measurements on the 
body burden of DDE, height and weight obtained in year 1995 in the linear equations for 
path analysis models in year 1997. The adequacy of model fit was determined by several 
statistics: a chi-square p-value > 0.05 if chi-square test statistic is close to 0, comparative 
fit index (CFI) > 90, adjusted goodness of fit index (GFI) > 90 and root mean square 
error of approximation (RMSEA) < 0.06. 
Results 
Out of 691 enrolled children, 632 performed PFTs in year 1995, 598 in year 1996 
and 558 in year 1997. However, DDE was measured only in years 1995 and 1997. A total 
of 328 (52 %) children in 1995 and 214 (61.7 %) children in 1997 had information on 
DDE. Table 5.1 shows the average anthropometric, pulmonary function and DDE 
exposure measures for each year. About 13 % had history of asthma, while prevalence of 
maternal and paternal asthma ranged from 3.4 % - 4.3 % and 5.3 % - 5.8 %, respectively 
over a period of 3 years. The prevalence of in-utero exposure to at least some amount of 
maternal smoking ranged from 29.4 % - 30 %. Similarly, the prevalence for ETS was 
32.3 % - 35.5 % (Table 5.2) 
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Boys had significantly higher FEV1 and FVC than girls in all years unadjusted for 
any covariate. However, FEV1/FVC ratio was higher in girls than boys suggesting much 
lower FVC in girls than boys (Table 5.3). Table 5.4 shows the Spearman’s correlations 
between DDE blood levels, anthropometric measures and pulmonary function. There was 
weak negative correlation between DDE levels and height, weight, FEV1 and FVC. 
Figure 5.1 demonstrates that height has a positive relationship with both FVC and 
FEV1 but higher level of DDE slightly blunts this relationship at higher levels of height in 
year 1995 (median age of participants 8 years). However, the effect of DDE on 
relationship of height with FVC and FEV1 is diminished in year 1997 (median age of 
participants 10 years). 
The final data set with repeated measurements contained 344 participants with 
1000 observations. All the linear mixed models were adjusted for age, height, weight, 
sex, breastfeeding status, exposure to in-utero maternal smoking and ETS. There were no 
significant associations between body burden of DDE and any pulmonary function 
parameter. As expected, height and weight had positive association with FVC and FEV1 
and no effect on FEV1/FVC ratio. The interaction term between sex and height was 
significant for FVC and FEV1/FVC ratio models but not for FEV1 model (Table 5.5). 
Path analysis at 1995 showed that DDE exposure had negative total effects on 
both height (direct: 1.3 cm per g/L of DDE, indirect: -0.16 cm per g/L of DDE, total: -
0.28 cm per g/L of DDE) and weight (total: -0.24 kg per g/L of DDE) after controlling 
for effects of age, sex, breast feeding and maternal smoking during pregnancy (Table 
5.6). Further, path analysis for the year 1995 demonstrated that DDE exposure did not 
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have any direct effects on any pulmonary function but had significant inverse indirect and 
total effects on both FVC (indirect: -0.20 L per g/L of DDE; total: -0.17 L per g/L of 
DDE) and FEV1 (indirect: -0.20 L per g/L of DDE; total: -0.15 L per g/L of DDE) 
(Tables 5.7 A and B). For year 1997, we included measurements on height, weight and 
DDE levels obtained in 1995. There were no total effects of body burden of DDE in 1997 
on either height or weight in 1997 after adjusting for height and weight in 1995 (Table 
5.8). However, there were significant inverse indirect effects of body burden of DDE 
measured in 1995 on both height and weight measured in 1997 mediated through its 
inverse effects on height and weight measured in 1995 (Figure 5.5 and 5.6). Similarly, 
DDE measured in year 1997 had no total effects on either FVC or FEV1 or FEV1/FVC 
but DDE measured in year 1995 had indirect inverse effects on FVC and FEV1 measured 
in year 1997 mediated through its effects on height and weight measured in both years 
(Figure 5.9 A-C).  
Figures 5.3 to 5.6 shows significant standardized direct and indirect effects of 
DDE exposure, height and weight on FVC and FEV1 at both years 1995 and 1997. The 
solid arrows represent the direct effects while the dotted arrows represent the indirect 
effects. The covariates with non-significant p-value for total effects were not depicted in 
these path diagrams but are included in Tables 5.7 A-C and 5.9 A-C. The path 
coefficients suggested that there was a direct effect of DDE exposure on height and 
weight, but no direct effect on either FVC or FEV1. However, as height and weight 
explains FVC and FEV1, the diminishing effects of DDE exposure on height and weight 
were carried forward towards FVC and FEV1 (indirect effect) with height and weight 
acting as intervening variables.  
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Discussion 
A study conducted in South-Hesse, Germany from 1995-1997 in children of age 8 
to 10 years suggest that dichlorodiphenyl dichloroethene (DDE) blood level may 
indirectly reduce lung function. Path analysis show negative correlations of DDE with 
height, weight and pulmonary function suggesting that height and weight may act as 
intervening/mediating factors in the association between DDE exposure and pulmonary 
function. The results from path analysis indicate that DDE exposure had direct inverse 
effects on reduced height and weight but not on pulmonary function. However, the 
inverse effect of DDE exposure was carried forward to FVC and FEV1 indirectly through 
its effect on height and weight in children of age 8 years. Although height and weight 
continued to have positive direct effects on both FVC and FEV1 these effects were 
attenuated by the inverse effects of DDE exposure on height and weight. Further analysis 
at age 10 years (1997) did not show any direct or indirect effect of DDE measured in 
1997 on height, weight or pulmonary function after adjusting for height and weight at age 
8 years. This shows that that with increase in age the direct effect of DDE on height and 
weight diminishes. Nevertheless, the inverse effect of DDE measured at age 8 years 
(1995) on height and weight persisted at age 10 years.   
DDE is known to affect endocrine system through its estrogenic and anti-
androgenic properties.105 Karmaus et al. reported that in-utero exposure to DDE is 
associated with reduced age at menarche by one year in a Michigan angler cohort.121 
High levels of DDE have also been found in girls with precocious puberty who migrated 
to Belgium from developing countries.122 Early age of menarche is associated with 
decrease in growth of height post-menarche, thus affecting the final adult height.130,159 A 
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prospective study by Ribas-Fito et al. found that increased prenatal DDE concentrations 
were associated with decreased height at 1, 4, and 7 years of age in both boys and girls.113 
On the other hand, a study by Gladen et al. suggested that prenatal exposure to DDE was 
associated with increased height at puberty in boys.116 In the same cohort from Hesse, 
Karmaus et al. demonstrated that growth during childhood was significantly reduced in 
girls with high DDE concentrations measured at 8 years of age but no effect was seen in 
boys.114  One possible explanation for the conflicting findings in previous studies may be 
the adjustment of intervening factors in explanatory models. The effects of DDE on 
height seem to vary by sex and DDE is directly associated with weight which in turn is 
directly associated with height. Therefore adjusting on weight may distort the true 
relationship between DDE exposure and height. Similarly when assessing the association 
between DDE and pulmonary function in children; adjusting on mediating variables 
weight and height may introduce mediator-outcome confounding.160 Additionally, 
introducing interaction term between height and DDE in the explanatory models may 
generate biased estimates because of mediator-exposure interaction.160 Another 
methodological problem arises from the fact that while analyzing pulmonary function in a 
population based study adjustment has to be made on height and weight. Our path 
analysis results may partially address these issues. The results suggested that DDE 
exposure had overall (total) inverse effect on height at age 8 years; but breakdown of this 
total effect showed a positive direct effect and inverse indirect effect. Our path diagram 
demonstrated that the indirect negative effect may have been mediated through weight 
(Figure 5.3 and 5.4). Thus, by using path analysis we were able to separate the 
confounding aspects of height and weight while assessing the association between DDE 
 93 
 
and pulmonary function at the same time taking measurement errors into consideration. 
We were however not able to corroborate these finding separately in boys and girls 
because of small sample size.  
There are some other important limitations to our study. We did not use predicted 
values for pulmonary function parameters and this may limit the interpretation of our 
results in the clinical settings. We did not have DDE exposure measured at age 9 years 
(1996). The average DDE level for 1996 generated through multiple imputation 
technique was slightly higher than years 1995 and 1997; having actual values for DDE 
would have been more reliable. Furthermore, it would have been more prudent to show 
the relationships between DDE, height, weight and pulmonary function through path 
analysis using repeated measurements. However, the structure of data did not allow the 
final model to converge and hence we conducted path analysis at a cross-sectional level.  
In addition to its effects on endocrine system DDE also alters immune function. 
There is evidence from both animal and human studies suggesting that DDE exposure is 
associated with increased production of cytokines and nitric oxide production in 
macrophages, leading to inflammatory reactions, cytokine imbalance and immune 
dysregulation.109-111 It also changes T-cell mediated response involving IL-4 which can 
induce epithelial cell proliferation, fibrosis, and mucus secretion to differing 
extents.109,112 A study investigating the effect of organochlorine compounds and lead on 
immune biomarkers in the present cohort demonstrated an increased levels of IgE, IgE 
count on basophils, and the reduction of eosinophilic granula at higher DDE 
concentrations.108 Such immunological changes due to persistent exposure to DDE may 
add to remodeling of both smaller and larger airways which is evident from 
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epidemiological studies reporting higher risk of developing asthma in children exposed to 
DDE.20,124-126 
Pulmonary function in children is determined by complex relationships between 
many factors like age, sex, race, height, weight and onset of puberty. These relationships 
are further complicated by exposure to DDE which is known to affect one or more of 
these determinants of pulmonary function. Although DDE exposure does not seem to 
directly influence pulmonary function, it does inversely affect height and weight, which 
in turn are related to pulmonary function. Therefore, poor growth in height and weight at 
an early age contributes to lower FVC and FEV1. Whether DDE exposure modifies 
physiology of airways leading to lower pulmonary function is unknown. However, our 
path analysis demonstrated that reduction in pulmonary function parameters are at least 
partially due to its effects on height and weight. Additionally, other research conducted in 
this cohort of children from federal state of Hesse, Germany has demonstrated reduction 
in childhood growth,114 increased IgE levels108 and increased risk of asthma and otitis 
media158 which would explain reduction in FVC and FEV1.  
To date, there has been no study investigating the association between DDE 
exposure and pulmonary function in children. In this study data on DDE exposure and 
PFT were assessed under standard conditions reducing the information bias. Use of path 
analysis allowed us to include the intervening factors in the explanatory models which 
helped disentangle the complex relationship between DDE exposure and pulmonary 
function. Finally, as in every longitudinal study, missing data was an issue which we 
overcame by multiple imputations.  
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In conclusion, we suggest that the relationship between height and pulmonary 
function is modified by DDE exposure during childhood. The use of path analysis 
improved the understanding of underlying directional or non-directional relationships, 
allowing the estimation of direct, indirect and total effects of height, weight and DDE 
exposure on pulmonary function. Further studies are needed to test this association in 
another sample, preferable from a region with continuous high DDT application. 
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Table 5.1: Baseline characteristics for children of age 8-10 years with pulmonary function data in the years 1995, 1996                     
and 1997 
 
Characteristic 
Year 1995 Year 1996 Year 1997 
N % Missing N % Missing N % Missing 
Sex 
Female 127 45.4 
0  
144 43.9 
0  
153 44.5 
0  
Male 153 54.6 184 56.1 191 55.5 
Doctor diagnosed  
asthma 
Yes 37 13.3 
1 
44 13.5 
1 
46 13.4 
2 
No 242 86.7 283 86.5 296 86.6 
Maternal asthma  
Yes 12 4.3 
3 
11 3.4 
1 
12 3.5 
2 
No 265 95.7 316 96.6 330 96.5 
Paternal asthma  
Yes 16 5.8 
5 
17 5.3 
4 
18 5.3 
5 
No 259 94.2 307 94.8 321 94.7 
Breast feeding 
Yes 244 87.5 
1 
279 85.3 
1 
293 85.4 
1 
No 35 12.5 48 14.7 50 14.6 
Maternal smoking  
during pregnancy  
(per day) 
>30 cigarettes 3 1.1 
3 
4 1.2 
5 
4 1.2 
7 
20-30 cigarettes 3 1.1 4 1.2 4 1.2 
11-20 cigarettes 11 4.0 13 4.0 14 4.3 
1-10 cigarettes 66 23.8 74 22.9 78 23.2 
None 194 70.0 228 70.6 237 70.3 
Environmental  
tobacco smoke (ETS) 
(per day) 
>30 cigarettes 2 0.7 
4 
5 1.6 
6 
5 1.5 
6 
20-30 cigarettes 5 1.8 5 1.6 5 1.5 
11-20 cigarettes 19 6.9 19 5.9 21 6.2 
1-10 cigarettes 72 26.1 75 23.3 79 23.4 
None 178 64.5 218 67.7 228 67.5 
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Table 5.2: Average anthropometric measures, pulmonary function parameters and DDE exposure  
 
Variable 
Year 1995 (n=280) Year=1996 (n=328) Year=1997 (n=344) 
Mean Median SD Mean Median SD Mean Median SD 
Age (years) 8.28 8 0.54 9.25 9 0.48 10.30 10 0.54 
Height (cm) 132.51 133 5.79 137.22 137 6.03 143.31 143.5 6.55 
Weight (kg) 30.02 29 6.48 32.96 32 6.81 38.63 37 8.86 
FEV1 (L) 1.80 1.78 0.28 1.88 1.88 0.29 2.13 2.12 0.32 
FVC (L) 2.05 2.01 0.33 2.25 2.25 0.33 2.50 2.47 0.39 
FEV1/FVC ratio (%) 87.93 88.49 6.16 83.81 84.96 7.18 85.39 85.77 5.44 
DDE (μg/L)* 0.41 0.29 0.43 0.55 0.51 0.30 0.42 0.32 0.39 
SD= Standard deviation, FEV1= Forced expiratory volume in one second, FVC=Forced expiratory capacity,  
DDE= Dichlorodiphenyl dichloroethylene 
*DDE levels were not measured in 1996 
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Table 5.3: Unadjusted average pulmonary function among boys and                              
girls (t-test) 
 
Year=1995  
Pulmonary 
function 
parameters  
Boys (n=153)  Girls (n=127)   
Mean SE Mean SE P-value 
FVC (L) 2.13 0.03 1.96 0.03 <.0001 
FEV1 (L) 1.85 0.02 1.73 0.02 0.0004 
FEV1/FVC (%) 87.20 0.54 88.81 0.47 0.0263 
Year=1996   
Pulmonary 
function 
parameters   
Boys (n=184) Girls (n=144)    
Mean SE Mean SE P-value 
FVC (L) 2.34 0.02 2.12 0.02 <.0001 
FEV1 (L) 1.93 0.02 1.81 0.02 <.0002 
FEV1/FVC (%) 82.50 0.56 85.48 0.52 0.0001 
Year=1997  
Pulmonary 
function 
parameters  
Boys (n=191) Girls (n=153)   
Mean SE Mean SE P-value 
FVC (L) 2.59 0.03 2.40 0.03 <.0001 
FEV1 (L) 2.17 0.02 2.09 0.03 0.0231 
FEV1/FVC (%) 83.99 0.40 87.13 0.40 <.0001 
SE= Standard error 
 
Table 5.4: Spearman’s correlations for DDE with anthropometric and                     
pulmonary function measures for years 1995 and 1997 
 
Variables 
Year=1995 (n=280) Year=1997 (n=344) 
Spearman's 
correlation 
P-value 
Spearman's 
correlation 
P-value 
DDE (μg/L)-Height (cm) -0.29 <.0001 -0.21 <.0001 
DDE (μg/L)-Weight (kg) -0.28 <.0001 -0.29 <.0001 
DDE (μg/L)-FEV1 (L) -0.15 0.0107 -0.15 0.007 
DDE (μg/L)-FVC (L) -0.20 0.001 -0.18 0.0006 
DDE (μg/L)-FEV1/FVC (%) 0.08 0.1572 0.09 0.1004 
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Table 5.5: Adjusted linear mixed models for pulmonary function, DDE exposure, height, weight and sex  
 
Covariates 
FVC (L) FEV1 (L) FEV1/FVC (%) 
Estimate SE P-value  Estimate SE P-value  Estimate SE P-value  
DDE (μg/L) -0.004 0.02 0.8172 0.002 0.02 0.8975 0.40 0.55 0.4755 
Height (cm) 0.03 0.00 <.0001 0.02 0.00 <.0001 0.01 0.06 0.826 
Weight (kg) 0.01 0.00 <.0001 0.01 0.00 <.0001 -0.08 0.05 0.096 
Sex: Female -0.36 0.20 0.0682 0.08 0.02 <.0001 12.7 6.71 0.0588 
Height*Sex 0.004 0.00 0.0066       -0.11 0.05 0.0212 
All models were additionally adjusted for breast feeding duration, history of maternal smoking during, current  
environmental tobacco smoke exposure 
Compound symmetry covariance matrix was selected based on lowest Akaike Information Criterion (AIC) 
Height*sex interaction had p-value >0.05 in explanatory model for FEV1; therefore not included in the final model 
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Table 5.6: The standardized direct, indirect and total effects of DDE along with other 
factors on height and weight from path analysis model at years 1995 
 
Covariates 
  Height Weight 
  Direct Indirect Total  Direct/Total 
DDE (μg/L) 
Estimate 1.3 -1.59 -0.28 -0.24 
SE 0.35 0.38 0.05 0.05 
P-value 0.0002 <.0001 <.0001 <.0001 
Age (years) 
Estimate -1.14 1.36 0.2 0.20 
SE 0.33 0.36 0.05 0.05 
P-value 0.0005 0.0002 <.0001 <.0001 
Weight (kg) 
Estimate 6.72   6.72   
SE 0.23   0.23   
P-value <.0001   <.0001   
Sex 
Estimate -0.14   -0.14   
SE 0.04   0.04   
P-value 0.0003   0.0003   
Breast feeding (weeks) 
Estimate -0.60 0.63 0.03 0.09 
SE 0.41 0.45 0.07 0.07 
P-value 0.1474 0.1650 0.6573 0.1613 
Maternal smoking during 
pregnancy 
Estimate 0.05 -0.09 -0.04 -0.01 
SE 0.33 0.36 0.05 0.05 
P-value 0.8684 0.7963 0.4586 0.7963 
Goodness of Fit Criteria: Chi-squared test statistic=5.7, p-value < 0.05; AGFI=0.9991; 
CFI=0.9936; RMSEA=0.0749 
Weight is the first endogenous variable determined by exogenous variables- DDE, age, breast 
feeding and maternal smoking during pregnancy and hence only has direct effects and no  
indirect effects. 
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Table 5.7 A: The standardized direct, indirect and total effects of DDE along with other factors on FVC from path analysis          
model at years 1995 
 
Covariates  
Total Direct Indirect 
Estimate SE P-value Estimate SE P-value Estimate SE P-value 
DDE (μg/L) -0.17 0.05 0.0015 0.03 0.04 0.4702 -0.20 0.04 <.0001 
Age (years) 0.05 0.05 0.3034 -0.10 0.04 0.0079 0.16 0.04 <.0001 
Height (cm) 0.50 0.05 <.0001 0.50 0.05 <.0001       
Weight (kg) 3.60 0.30 <.0001 0.26 0.05 <.0001 3.34 0.34 <.0001 
Sex -0.27 0.04 <.0001 -0.20 0.04 <.0001 -0.07 0.02 0.0007 
Breast feeding (weeks) 0.02 0.07 0.7238 0.02 0.05 0.7349 0.04 0.05 0.3775 
Maternal smoking during pregnancy -0.05 0.06 0.3412 -0.03 0.04 0.4705 -0.02 0.04 0.5365 
Environmental tobacco smoke 0.02 0.04 0.5858 0.02 0.04 0.5858       
Goodness of Fit Criteria: Chi-squared test statistic=5.7, p-value < 0.05; AGFI=0.9991; CFI=0.9936; RMSEA=0.0749
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Table 5.7 B: The standardized direct, indirect and total effects of DDE along with other factors on FEV1 from path analysis              
model at years 1995 
 
Covariates 
Total Direct Indirect 
Estimate SE P-value Estimate SE P-value Estimate SE P-value 
DDE (μg/L) -0.15 0.06 0.0053 0.04 0.04 0.3555 -0.20 0.04 <.0001 
Age (years) 0.07 0.05 0.1935 -0.08 0.04 0.0424 0.15 0.04 <.0001 
Height (cm) 0.47 0.05 <.0001 0.47 0.05 <.0001    
Weight (kg) 3.41 0.32 <.0001 0.27 0.05 <.0001 3.14 0.4 <.0001 
Sex -0.22 0.04 <.0001 -0.16 0.04 0.0001 -0.07 0.02 0.0008 
Breast feeding (weeks) 0.06 0.07 0.3948 0.02 0.05 0.7088 0.04 0.04 0.3857 
Maternal smoking during pregnancy -0.07 0.06 0.2469 -0.05 0.05 0.3247 -0.02 0.04 0.538 
Environmental tobacco smoke 0.03 0.05 0.5652 0.03 0.05 0.5652    
Goodness of Fit Criteria: Chi-squared test statistic=5.7, p-value < 0.05; AGFI=0.9991; CFI=0.9931; RMSEA=0.0753
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Table 5.7 C: The standardized direct, indirect and total effects of DDE along with other factors on FEV1/FVC from path              
analysis model at years 1995 
 
Covariates 
Total Direct Indirect 
Estimate SE P-value Estimate SE P-value Estimate SE P-value 
DDE (μg/L) 0.07 0.06 0.2412 0.03 0.06 0.6079 0.04 0.03 0.0440 
Age (years) 0.002 0.06 0.9688 0.03 0.06 0.5904 -0.03 0.03 0.0569 
Height (cm) 0.12 0.08 0.1303 -0.12 0.08 0.1303       
Weight (kg) -0.79 0.47 0.0897 -0.02 0.07 0.8185 -0.78 0.51 0.1298 
Sex 0.13 0.05 0.0157 0.12 0.06 0.0378 0.02 0.01 0.1630 
Breast feeding (weeks) 0.06 0.07 0.3664 0.07 0.07 0.3287 -0.01 0.01 0.6122 
Maternal smoking during pregnancy -0.02 0.06 0.7895 -0.02 0.06 0.7317 0.01 0.01 0.5111 
Environmental tobacco smoke -0.001 0.06 0.9836 -0.001 0.06 0.9836       
Goodness of Fit Criteria: Chi-squared test statistic=5.7, p-value < 0.05; AGFI=0.9992; CFI=0.9894; RMSEA=0.0749
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Table 5.8: The standardized direct, indirect and total effects of DDE along with other factors on height and weight from                  
path analysis model at years 1997 
 
Height in year 1997 
Covariates Total Direct Indirect 
Estimate SE P-value Estimate SE P-value Estimate SE P-value 
DDE in year 1997 (μg/L) 0.02 0.02 0.4313 0.02 0.02 0.3948 -0.001 0.00 0.365 
DDE in year 1995 (μg/L) -0.24 0.05 <.0001       -0.24 0.05 <.0001 
Height in year 1995 (cm) 0.92 0.02 <.0001 0.92 0.02 <.0001       
Weight in year 1995 (kg) 1.44 0.54 0.008       1.44 0.54 0.008 
Weight in year 1997 (kg) 0.04 0.03 0.1594 0.04 0.03 0.1594       
Age (years) 0.02 0.02 0.2757 0.02 0.02 0.2961 0.001 0.00 0.3043 
Sex -0.03 0.04 0.3937 0.11 0.02 <.0001 -0.14 0.04 0.0001 
Breast feeding (weeks) 0.04 0.07 0.5174 0.04 0.03 0.1324 0.003 0.06 0.9628 
Maternal smoking during pregnancy  0.01 0.05 0.8168 0.03 0.02 0.2229 -0.02 0.05 0.7756 
Weight in year 1997 
Covariates Total Direct Indirect 
Estimate SE P-value Estimate SE P-value Estimate SE P-value 
DDE in year 1997 (μg/L) -0.03 0.02 0.265 -0.03 0.02 0.265       
DDE in year 1995 (μg/L) -0.19 0.05 <.0001       -0.19 0.05 <.0001 
Weight in year 1995 (kg) 0.92 0.01 <.0001 0.92 0.01 <.0001       
Age (years) 0.03 0.02 0.16 0.03 0.02 0.16       
Breast feeding (weeks) 0.08 0.07 0.2039 0.03 0.03 0.246 0.05 0.06 0.4054 
Maternal smoking during pregnancy  0.01 0.05 0.7914 0.01 0.02 0.6888 0.01 0.05 0.9225 
Goodness of Fit Criteria: Chi-squared test statistic=33.1, p-value < 0.05; AGFI=0.898; CFI=0.994; RMSEA=0.048
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Table 5.9 A: The standardized direct, indirect and total effects of DDE along with other factors on FVC from path analysis          
model at years 1997 
 
Covariates 
Total Direct  Indirect 
Estimate SE P-value Estimate SE P-value Estimate SE P-value 
DDE in year 1997 (μg/L) 0.01 0.04 0.836 0.01 0.03 0.8675 0.002 0.02 0.8945 
DDE in year 1995 (μg/L) -0.18 0.04 <.0001       -0.18 0.04 <.0001 
Age (years) 0.05 0.04 0.1421 0.03 0.03 0.3179 0.02 0.01 0.1759 
Height in year 1997 (cm) 0.48 0.10 <.0001 0.48 0.10 <.0001       
Weight in year 1997 (kg) 0.278 0.05 <.0001 0.26 0.04 <.0001 0.02 0.02 0.1771 
Height in year 1995 (cm) 0.52 0.04 <.0001 0.08 0.11 0.4726 0.44 0.10 <.0001 
Weight in year 1995 (kg) 1.04 0.31 0.0007       1.04 0.31 0.0007 
Sex -0.25 0.04 <.0001 -0.23 0.04 <.0001 -0.03 0.02 0.2686 
Breast feeding (weeks) 0.0004 0.06 0.9956 -0.04 0.04 0.3166 0.04 0.05 0.397 
Maternal smoking during pregnancy -0.06 0.05 0.252 -0.07 0.04 0.0612 0.01 0.04 0.8344 
Environmental tobacco smoke 0.08 0.04 0.0407 0.08 0.04 0.0407       
Goodness of Fit Criteria: Chi-squared test statistic=33.1, p-value < 0.05; AGFI=0.898; CFI=0.994; RMSEA=0.048
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Table 5.9 B: The standardized direct, indirect and total effects of DDE along with other factors on FEV1 from path analysis          
model at years 1997 
 
Covariates 
Total Direct Indirect 
Estimate SE P-value Estimate SE P-value Estimate SE P-value 
DDE in year 1997 (μg/L) 0.02 0.04 0.6785 0.02 0.04 0.6909 0.002 0.02 0.9072 
DDE in year 1995 (μg/L) -0.17 0.04 <.0001       -0.17 0.04 <.0001 
Age (years) 0.08 0.04 0.0536 0.06 0.04 0.1345 0.02 0.02 0.1596 
Height in year 1997 (cm) 0.53 0.12 <.0001 0.53 0.12 <.0001       
Weight in year 1997 (kg) 0.23 0.05 <.0001 0.23 0.05 <.0001       
Height in year 1995 (cm) 0.51 0.05 <.0001 0.01 0.12 0.9419 0.51 0.11 <.0001 
Weight in year 1995 (kg) 0.21 0.05 <.0001       0.21 0.05 <.0001 
Sex -0.13 0.04 0.0021 -0.11 0.04 0.0055 -0.02 0.03 0.467 
Breast feeding (weeks) 0.04 0.07 0.5065 0.001 0.05 0.9879 0.04 0.05 0.3583 
Maternal smoking during pregnancy -0.09 0.06 0.1203 -0.1 0.04 0.0213 0.01 0.04 0.7723 
Environmental tobacco smoke 0.07 0.04 0.1091 0.07 0.04 0.1091       
Goodness of Fit Criteria: Chi-squared test statistic=33.7, p-value < 0.05; AGFI=0.909; CFI=0.994; RMSEA=0.043
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Table 5.9 C: The standardized direct, indirect and total effects of DDE along with other factors on FEV1/FVC from                           
path analysis model at years 1997 
 
Covariates 
  
Total Direct Indirect 
Estimate SE P-value Estimate SE P-value Estimate SE P-value 
DDE in year 1997 (μg/L) 0.06 0.18 0.7405 0.06 0.18 0.7558 0.004 0.00 0.4165 
DDE in year 1995 (μg/L) 0.02 0.19 0.9107 -0.01 0.19 0.9574 0.03 0.02 0.0441 
Age (years) 0.03 0.05 0.6091       -0.001 0.00 0.8015 
Height in year 1997 (cm) 0.07 0.17 0.6749 0.07 0.17 0.6749       
Weight in year 1997 (kg) -0.09 0.07 0.209 -0.09 0.07 0.2035 0.003 0.01 0.6893 
Height in year 1995 (cm) -0.06 0.07 0.3977 -0.13 0.17 0.4582 0.07 0.15 0.6749 
Weight in year 1995 (kg) -0.17 0.09 0.0607       -0.17 0.09 0.0607 
Sex 0.3 0.05 <.0001 0.28 0.05 <.0001 0.02 0.02 0.4248 
Breast feeding (weeks) 0.09 0.07 0.1836 0.09 0.07 0.1684 -0.004 0.01 0.7591 
Maternal smoking during pregnancy -0.06 0.06 0.3292 -0.06 0.06 0.316 0.001 0.01 0.8656 
Environmental tobacco smoke -0.02 0.06 0.765 -0.02 0.06 0.765       
Goodness of Fit Criteria: Chi-squared test statistic=28.6, p-value < 0.05; AGFI=0.906; CFI=0.995; RMSEA=0.044
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I. Relationship between DDE (μg/L) and height (cm) with FVC (L)            II. Relationship between DDE (μg/L) and height (cm) with FEV1 (L) 
 
 
Figure 5.1: Three dimensional scatter plot showing relationship between DDE and height with FVC and FEV1 in year 1995 (median 
age: 8 years) 
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      I. Relationship between DDE (μg/L) and height (cm) with FVC (L)       II. Relationship between DDE (μg/L) and height (cm) with FEV1 (L) 
 
 
 
 
Figure 5.2: Three dimensional scatter plot showing relationship between DDE and height with FVC and FEV1 in year 1997 (median 
age: 10 years) 
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Figure 5.3: Analytical path model exploring the standardized direct and indirect effects of DDE exposure, height, weight and FVC at 
year 1995 (path coefficients from Table 5.6, and 5.7 A)  
 
The path coefficients represented by solid arrows are direct effects while those represented by dashed arrows are indirect effects. The coefficients 
for covariates with non-significant total effects are not depicted in this diagram.  
Height in year 
1995 
DDE in year 1995 
Weight in year 
1995 
FVC in year 1995 
-0.20 
6.72 
0.50 1.30 
-0.20 
-0.14 
0.26 -0.24 
-1.59 
Sex: Female 
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Figure 5.4: Analytical path model exploring the standardized direct and indirect effects of DDE exposure, height, weight and FEV1 at 
year 1995 (path coefficients from Table 5.6 and 5.7 B) 
 
The path coefficients represented by solid arrows are direct effects while those represented by dashed arrows are indirect effects. The coefficients 
for covariates with non-significant total effects are not depicted in this diagram. 
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Figure 5.5: Analytical path model exploring the standardized direct and indirect effects of DDE exposure, height, weight and FVC at 
year 1997 (path coefficients from Table 5.6, 5.8 and 5.9 A) 
 
The path coefficients represented by solid arrows are direct effects while those represented by dashed arrows are indirect effects. The coefficients 
for covariates with non-significant total effects are not depicted in this diagram.  
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Figure 5.6: Analytical path model exploring the standardized direct and indirect effects of DDE exposure, height, weight and FEV1 at 
year 1997 (path coefficients from Table 5.6, 5.8 and 5.9 B) 
 
The path coefficients represented by solid arrows are direct effects while those represented by dashed arrows are indirect effects. The coefficients 
for covariates with non-significant total effects are not depicted in this diagram.   
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6.17 
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CHAPTER 6 
DISCUSSION 
According to the World Health Organization’s report on environmental burden of 
diseases 20 % of lower respiratory tract diseases in developed countries are because of 
environmental causes.1 Most commonly investigated exposures associated with 
respiratory diseases and pulmonary function are air pollution, indoor and outdoor 
allergens, tobacco smoke and exposure to chemical irritants. In children research related 
to associations between these exposures are often focused on risk of asthma and lower 
respiratory tract infections and rarely provide information on pulmonary function. 
However, since the development of pulmonary function stretches from newborns to 
young adulthood it is important to study these exposures in relation to pulmonary 
function as it may have long term consequences. In this dissertation, we studied three 
such environmental exposures- sensitization to house dust mite, joint effects of maternal 
smoking during pregnancy and adolescent smoking and dichlorodiphenyl dichloroethene 
(DDE) in relation to pulmonary function in children and late adolescents. 
The first hypothesis investigated whether there is an association between 
immunological response to HDM and pulmonary function during late adolescence (18 
years of age) after controlling for other atopic conditions. Immunological responses to 
HDM allergen were measured in terms of wheal size on SPT. To investigate this aim we
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used data from the Isle of Wight (IOW) birth cohort, which was established in 1989 with 
the aim to study the natural history of asthma and allergic conditions. Our study is one of 
the first to explore the direct association between wheal size and pulmonary function. In 
second hypothesis we investigated the independent and joint effects of maternal smoking 
during pregnancy and adolescent smoking on pulmonary function in adolescents of age 
18 years in IOW birth cohort. Although there is an abundance of literature on 
independent effects of maternal smoking during pregnancy and adolescent smoking on 
pulmonary function, little information is available on the joint effects of gestational and 
adolescent smoking, their underlying pathways, and relationships between these exposure 
and other determinants of pulmonary function. In third hypothesis our aim was to 
investigate the effects of persistent body burden of DDE on pulmonary function in a 
cohort of children aged 8 to 10 years in Germany between 1994 and 1997. This study is 
one of first to investigate this association although previous studies have shown link 
between DDE exposure, asthma and atopic conditions. 
Interpretation of Findings 
Hypothesis 1 
In this study we found that increase in wheal diameter on SPT was associated 
with reduced FEV1, FEV1/FVC ratio and FEF25-75% and increased FeNO levels. Further 
we also found that although FEV1 and FVC were reduced in adolescents with history of 
asthma wheezing episodes, adolescents without history of wheezing also demonstrated 
greater reduction in FEV1/FVC and FEF25-75% with every 1 mm increase in wheal 
diameter.  
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Previous studies have explored HDM exposure mostly in relation to risk of 
asthma and atopic diseases, bronchial hyperresponsiveness, FeNO and percent predicted 
FEV1 levels.
24,42,44,45 Although one study by Koshak et al. reported increased severity of 
asthma with increased wheal diameter on SPT to HDM, no other studies have 
investigated the association between wheal size and pulmonary function parameters.62 
In the present study, every 1 mm increase in wheal diameter, we found a 
reduction of pulmonary function and an increase in exhaled nitric oxide (FeNO) levels, 
suggesting that participants reactive to HDM on SPT but with no history of asthma or 
wheezing attacks still experience reduction pulmonary function. This may be explained 
by a possible inflammation of the airways or a reduced airway growth. Although in 
clinical settings an individual is usually considered as sensitive to HDM allergen if the 
wheal diameter is ≥ 3 mm, our results related to degree of sensitization suggested that 
reduction in pulmonary function only becomes evident at wheal diameter of > 5 mm.  
Hypothesis 2 
The findings of this investigation supported the hypothesis that maternal smoking 
during pregnancy and current adolescent smoking have inverse effect on pulmonary 
function in adolescents after accounting for the intervening effect of active smoking in 
adolescence. We tested this hypothesis first by using standard linear regression 
techniques. Our results indicated that smoking during pregnancy and adolescence had 
differential effects on pulmonary function among boys and girls. We found that girls are 
more vulnerable to effects of smoking than boys. Exposure to maternal smoking during 
fetal period is associated with increased adolescent smoking and decreased height and 
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weight in the offspring. Additionally, adolescent smoking, height, and weight are also 
important determinants of pulmonary function making them intervening variables on 
pathway between gestational smoking and pulmonary function at 18 years of age. Hence, 
conditioning on these intervening variables may generate biased estimates in linear 
regression. In order to address the issue of intervening variables, we conducted path 
analysis separately in boys and girls. Path analysis first demonstrated that adolescent 
smoking had direct inverse effect on FEV1/FVC ratio in boys. Gestational smoking did 
not have any direct effects on FEV1/FVC but its effects were mediated through 
adolescent smoking. Similarly in girls, adolescent smoking had direct inverse effect on 
FEV1 and effects of maternal smoking during pregnancy were mediated through 
adolescent smoking. However, path analysis also demonstrated that the adverse effects on 
FEV1/FVC and FEF25-75% in girls were mainly due to maternal smoking during pregnancy 
and adolescent smoking did not contribute significantly to the reduction in these 
pulmonary function measures. 
Not many studies have investigated the joint effects of maternal smoking during 
pregnancy and adolescent smoking on pulmonary function in adolescents. Few studies 
who have investigated this association were limited either by lack of generalizability94 or 
small sample size of participants with exposure to maternal smoking95 or lack of 
information on current smoking status.93 However, our findings related to differences in 
boys and girls were comparable to those by Holmen et al. and Gold et al.14,89 Both these 
studies investigated the independent effects of adolescent smoking on pulmonary 
function after adjusting for passive smoking. Holmen et al. in a cohort of 13-18 years old 
participants from Norway found that adolescent smoking was associated with reduction 
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in pulmonary function only in girls. Although Gold et al. found that a lower FEV1/FVC 
ratio and a lower FEF25-75% in both boys and girls of age 10 -18 years were associated 
with adolescent smoking, they found that girls were more vulnerable to adverse effects of 
smoking and had lower growth of pulmonary function than boys.14 However in our study 
we found that girls were more affected by gestational smoking than personal smoking. 
Additionally, previous studies have reported increased FeNO levels in infants and young 
children who were exposed to maternal smoking during pregnancy.148,149 To our 
knowledge no study has examined the relationship between gestational smoking and 
FeNO in adolescents. In our study we found that both maternal smoking during 
pregnancy and adolescent smoking had independent as well as joint positive effects on 
FeNO. 
One of the advantage of our study is that we used path analysis to disentangle the 
relationships between determinants of pulmonary function in different periods of child 
development i.e. gestation to adolescence. Standard regression analysis does not take into 
consideration the temporal sequence and thus is ill-suited for modeling relationships 
which are composed of effects mediated through intervening variables. Path analysis on 
the other hand accommodates intervening variables in the model since it is based on both 
conceptual theories and mathematical equations. Pulmonary function during childhood 
and adolescent period is determined by complex relationships between many factors like 
age, sex, height, weight, race and smoking status. Failure to understand the underlying 
‘causal’ pathways and relationships between these factors can lead to unintentional 
adjustment on intervening or mediating variables. This may not only distort the causal 
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pathway but may also lead to an over-adjustment bias affecting the precision of the 
relationship between exposure and outcome .161  
Hypothesis 3: 
Our third hypothesis was – persistent body burden of dichlorodiphenyl 
dichloroethene (DDE), a by-product of the pesticide dichlorodiphenyl trichloroethane 
(DDT), affects pulmonary function in childhood, directly or indirectly via its effect on 
height and weight in children. In our first step, we found that there was a weak 
correlation between DDE exposure and - height, weight, FEV1 and FVC. Next we used, 
linear mixed models to explore the association between DDE exposure and pulmonary 
function pattern. Although our repeated measurement analysis showed an association of 
height, weight and sex with pulmonary function there was no significant association 
between DDE exposure and pulmonary function. However, our path analysis showed that 
DDE exposure measured at age 8 years (1995) had direct inverse effects on height and 
weight measured at age 8 years and indirect inverse effects on height and weight 
measured at age 10 years (1997). Further, it also suggested that DDE exposure had 
indirect effects on FEV1 and FVC mediated through its effects on height and weight in 
children of age 8 years. We also observed indirect inverse association between DDE 
exposure measured at age 8 years and FEV1 and FVC measured at age 10 years mediated 
through height and weight measured at both 8 and 10 years. However, there was no 
association between DDE exposure measured at age 10 years and FEV1 and FVC 
measured also at age 10 years.  
 120 
 
DDE is an exposure which is known to affect three important determinant of 
pulmonary function: height, weight and immune function. There are conflicting reports 
on effects of DDE on height. Some studies have suggested that DDE reduced height in 
both boys and girls;113 while other have reported that it reduced height only in girls114 
while increased height in boys during pubertal period.116 Literature also shows that DDE 
exposure leads to early puberty in girls through its estrogenic effects.121 Our results 
showed that DDE exposure was directly related to reduction in height and weight at age 8 
years and indirectly at age 10 years, although we were not able to test this hypothesis 
separately in boys and girls. Both height and weight are related to an increase in lung 
capacity and therefore any exposure that adversely affects height and weight should 
affect FVC. Our results corroborated this hypothesis. Additionally, role of DDE exposure 
in dysregulation of immune function may also lead to remodeling of airways. Previous 
study conducted in the same cohort as the present study have also shown that higher DDE 
concentrations increased levels of IgE, IgE count on basophils, and the reduction of 
eosinophilic granula.  
Study Limitations 
The major limitation of this dissertation is related to lack of use of predicted 
values for pulmonary function parameters and this may limit the interpretation of our 
results in clinical settings. The percent of predicted values are recommended by 
American Thoracic Society for diagnosing asthma. Although there is plethora of 
published prediction/reference equations for spirometric indices for European population, 
the generalizability of these equations is questionable as many are based on data collected 
decades ago on small numbers of subjects specific to a set of population and so may 
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affect their applicability to this cohort. However, the new reference equations for wider 
age range and multi-ethnic groups developed as a part of Global Lung Function Initiative 
(GLI) could be used in future studies.127 In addition to this limitation there some other 
limitations related to each hypotheses. Regarding hypothesis 1, while exploring 
association between HDM sensitivity we adjusted for sensitivity to other indoor and 
outdoor allergens. Often sensitivity to HDM is related with sensitivity to other indoor 
allergens especially cats and dogs. This correlation could have biased the final estimates 
in linear regression models; however, it provided the net effect of house dust mite 
sensitization. In hypothesis 2, information on smoking during pregnancy was self-
reported. Because of negative attitude towards smoking during pregnancy this 
information may have been underestimated and it was not validated by objective 
measurements. Under-reporting of smoking may have biased our estimates for maternal 
smoking during pregnancy towards the null. Another important limitation is small sample 
sizes in four smoking exposure categories in boys and girls in linear regression models 
which results in a lower statistical power to detect significant differences. In the third 
hypothesis the major limitation was that we were not able to test our hypothesis 
separately in boys and girls using path analysis. DDE is known to affect height and 
weight differently in boys and girls and thus, may have differential effects on pulmonary 
function in boys and girls. However, because of small sample size our path analysis 
models were not able to generate positive convergence estimates for maximum likelihood 
optimization method. 
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Public Health Implications 
Hypothesis 1: 
Allergy is a major health problem in the Western countries. The prevalence of 
asthma is high in the populations with a high prevalence of atopy. In general, asthma 
diagnoses are based on clinical presentation of symptoms and reduction in FEV1. But 
often the history of asthmatic symptoms like wheezing and nocturnal cough provided by 
children or their parents is unreliable and it is not possible to diagnose airway obstruction 
on physical exam. Additionally, diagnosis of slight airway obstruction is difficult as 
patients may not exhibit clinical symptoms associated with it. In such situations the 
reduction in pulmonary function may go undetected unless the physician orders for 
pulmonary function tests. In these settings, wheal diameter may serve as a potential 
indicator of underlying abnormal pulmonary function. Monitoring of individuals reactive 
to HDM but with no history of asthma may be beneficial as it may alert physicians to 
abnormality in pulmonary function and in the long term may reduce the burden of 
chronic respiratory diseases in adults. 
Hypothesis 2: 
The findings from hypothesis two have both clinical and public health 
significance. The increased FeNO levels and reduction in FEV1/FVC and FEF25-75% 
values found in girls suggest that gestational smoking leads to chronic inflammation and 
remodeling in small airways along with larger airways. These findings are especially 
important because lower pulmonary function during adolescence may possibly lead to 
chronic obstructive pulmonary disease and small airway disease in adulthood. The 
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findings demonstrate that not only tobacco exposure has differential inverse effects on 
pulmonary function among adolescent boys and girls, but maternal smoking during 
pregnancy has a measurable adverse effect on the pulmonary function which is 
independent of any direct use of cigarettes by adolescents. Our results corroborated the 
need of intervention strategies of tobacco cessation in adolescents and women of 
reproductive age. Furthermore, reduction in maternal smoking during pregnancy may 
also lead to reduction in adolescent smoking which in turn may not only lower the burden 
of chronic respiratory diseases but also other chronic diseases like cardiovascular 
diseases and cancers. 
Hypothesis 3: 
Although the pesticide dichlorodiphenyl trichloroethane (DDT) has been banned 
for more than three decades now, its principal metabolite DDE remains a global public 
health issue. Its adverse effects on more than one determinant of pulmonary function 
namely height and weight makes it difficult to determine its true effect on pulmonary 
function. In this study we used a more sophisticated approach of path analysis to study 
the interrelationships between DDE exposure, height, weight and pulmonary function. 
Although our results suggested that the adverse effects of DDE on pulmonary function 
were mediated through height and weight, results from previous studies in the same 
cohort in Hesse, Germany suggest DDE exposure may possibly lead to structural damage 
to airways through its effects of immune system. However, this hypothesis can only be 
corroborated by histo-pathological studies. We must point out that although our study 
population belonged to a developed country, the investigation of this hypothesis in a 
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population with high use of DDT for agricultural or malaria prevention purposes would 
give a clearer picture of the impact of DDE on pulmonary function. 
Summary 
The ultimate goal of this dissertation was to enhance our knowledge and 
understanding of how environmental exposures, namely sensitization to HDM, 
gestational smoking and adolescent smoking, and DDE, impact pulmonary function in 
children and adolescents. We started by exploring the association between wheal size on 
SPT for HDM and pulmonary function in adolescents of age 18 years in hypothesis 
one.We found that increased wheal diameter on SPT was associated with reduced 
pulmonary function in adolescents of age 18 years irrespective of history of wheezing 
attacks. Our results also demonstrated that wheal diameter on SPT could serve as a 
potential indicator of abnormal pulmonary function in asymptomatic individuals 
sensitized to HDM. With hypothesis two we assessed the joint effects of gestational and 
adolescent smoking on pulmonary function. The results suggest that girls are more 
vulnerable to smoking effects than boys. Path analysis further demonstrated that not only 
adolescent tobacco exposure has differential inverse effects on pulmonary function 
among adolescent boys and girls, but also gestational smoking has a measurable adverse 
effect on the pulmonary function, independent of any direct use of cigarettes by 
adolescents. Finally, in our third hypothesis we investigated associations between body 
burden of DDE exposure and pulmonary function parameters in children of age 8-10 
years. Previous research in the field of DDE and respiratory health has been limited to 
investigations of upper and lower respiratory illnesses and risk of asthma. We were able 
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to demonstrate an indirect association of DDE with pulmonary function mediated through 
height and weight.  
These results emphasize the importance of the adverse effects of environmental 
exposures on pulmonary function in children and adolescents. The reduction in 
pulmonary function in children and adolescents is associated with early onset of chronic 
respiratory diseases in adulthood leading to increased burden of respiratory diseases and 
impaired quality of life. Therefore, early detection of reduction in pulmonary function 
may not only reduce the burden of respiratory diseases on healthcare system but may also 
improve the health and quality of life at individual level. Our first two hypotheses were 
investigated in a population with high prevalence of allergy and smoking and the third 
hypothesis related to DDE exposure was investigated in a cohort from a developed 
country with lower levels of DDE than detected in children from developing and 
underdeveloped countries. Future research should be focused on investigating these 
associations in a more generalizable population of children in longitudinal studies..
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